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ABSTRACT OF THE DISSERTATION
Dissecting the neural circuits mediating pain-induced negative affect and drug-seeking behaviors
by
Tamara Markovic
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2021
Professor Jose A. Morón-Concepción, PhD. Chair
Understating the function of neural circuits and the state-depended adaptations within them
is one of the fundamental aims in the field of neuroscience. With recent technical developments in
monitoring circuit dynamic, such as calcium (Ca2+) imaging, visualizing synaptic connections
using viral approaches and manipulating neuronal activity in cell-specific manner such as
optogenetic and chemogenetics, we are now able to mechanistically link the activity and function
of neural circuits with behavioral outcomes.
Using the above-mentioned techniques, I demonstrate that pain induces somatic
adaptations in the Ventral Tegmental Area (VTA) dopamine (DA) neurons to drive anhedonia-like
behaviors. Pain is a complex phenomenon composed of sensory and emotional-affective
components. Common line of treatments for pain are opioids whose efficacy diminishes as pain
changes from acute to chronic. As pain persists, the presence of negative affective states can lead
to the development of negative emotional states such as dysphoria, anhedonia and anxiety. These
co-morbid disturbances can lead to depression and opioid misuse, consequently escalating into life
threatening events such as suicide attempts or accidental opioid overdoses. Emerging evidence
from human and preclinical studies show deficits in emotional decision making, reward evaluation
xii

and reward seeking, or motivation in pain states. These alterations in reward processing and
decreased motivation represent key components of pain-induced negative affective states that can
lead to the development of anhedonia and depression.
Within the mesolimbic reward pathway, VTA DA neurons projecting to the nucleus
accumbens (NAc) have a prominent role in reward processing and motivated behavior. One of the
main mediators of the VTA DA neuron activity are inhibitory GABAergic inputs. These inhibitory
GABAergic inputs arise from the rostromedial tegmental nucleus (RMTg), NAc, ventral pallidum
(VP), and bed nucleus of stria terminalis (BNST), among others, and make up a majority of the
synaptic input. Furthermore, RMTg GABAergic inputs are highly controlled by the  opioid
receptor (MOR) system which is downregulated in the presence of pain as demonstrated by
previous work form our lab and others. Thus, I hypothesized that pain induces adaptations in the
VTA DA by disruption of MOR function at the presynaptic GABAergic terminals in the VTA,
consequently leading to anhedonia-like behaviors. Indeed, I found that pain increases RMTg
inhibitory tone onto VTA DA neurons making them less excitable. In line with this finding a
decreased activity of VTA DA neurons is associated with reduced motivation for natural rewards,
consistent with anhedonia-like behavior. Furthermore, I report that enhancing activity of NAcprojecting DA neurons in the VTA using chemogenetics is sufficient to overcome pain-induced
reduction in motivated behavior. I also demonstrate that the decrease in sucrose consumption
induced by the presence of pain can be overcome by increasing the concentration of the sucrose
reward, further suggesting impaired hedonic responses in pain. Lastly, I was able to mimic the
effects of pain on sucrose consumption by chemogenetic stimulation of RMTg GABA neurons.
Overall, the results generated in this dissertation represent a crucial step in understanding the
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neural circuit mechanisms underlying the emotional component of pain and may provide novel
targets for the treatment of pain-induced negative affect.
It is well known that we are facing a pain crisis. In addition to that about 30 percent of pain
patients prescribed opioids for their symptoms misuse them. Furthermore, even with the current
maintenance medications and treatments, 40 to 60 percent of patients relapse after periods of
abstinence. Long term maintenance of associations between the reinforcing effects of the drug and
the environment in which they are administered are a leading cause of relapse. Numerous studies
indicate that glutamatergic transmission in the dHPC is crucial for the formation of the learned
associations between the rewarding effects of opioids and the context in which they are given.
Additionally, dHPC projects to NAc, a key area for processing of cue-predicted reward related
behaviors. Thus, I hypothesized that dHPC is necessary for relapse in drug seeking behaviors
induced by drug-associated contextual cues. To assess the role of dHPC in reinstatement of opioid
drug-seeking I used a chemogenetic approach to selectively silence dHPC excitatory neurons.
Findings presented in this dissertation demonstrate that silencing excitatory dHPC neurons during
re-exposure to drug-context significantly attenuates drug-seeking reinstatement. In addition,
silencing dHPC did not alter either short-term or long-term memory as measured using an object
location task. This result demonstrates that the observed attenuation of reinstatement is not due
memory retrieval impairment but rather to a selective disruption of drug-reward association. While
these findings uncover the necessity of dHPC in cue induced reinstatement, the exact inputs
mediating the activity of dHCP are yet to be uncovered. To this end I am utilizing viral approaches
and chemogenetics to further dissect the circuit driving contextual-cue induced reinstatement of
drug-seeking.

xiv

Together, studies presented in this dissertation generate important findings that further
enrich our understating of pathological changes happening within neural circuit mediating paininduced negative affect and contextual-cue induced reinstatement of drug seeking, and how
manipulations of these circuits can alleviate negative emotional states associated with these
disorders.
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Chapter 1
Introduction
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1.1 Pain Crisis
Around 30% of the population in the United State of America (USA) reported experiencing
chronic, recurring or persistent pain.1,2 In fact, the number of people living with pain condition
tops the number of patients suffering from cancer, heart disease and diabetes combined.3 This
alarming rate of patients suffering from chronic or severe pain represent a major financial burden
in the USA by contributing up to 600 billion dollars a year in healthcare costs, lost productivity
and disability programs.1,4 More importantly, pain has devastating consequences on the quality of
life of patients, interfering with their daily activities and well-being, which affects their families
and society all together.
Due to the concern that pain was undermanaged, based on the recommendations by Dr.
James Campbell in 1995 to the American Pain Society, pain was introduced as a fifth vital sign.5
The goal of this approach was to obtain the essential information for medical practitioners in order
to provide adequate pain management. However, this further showed that pain evaluation and
management is more intricate than originally thought.
Due to their high potency in producing pain relief opioid-based analgesics have become
the first line of treatment for pain. With pain being qualified as a fifth vital sign, thus requiring
medical practitioners to provide sustained pain relief and alleviate suffering, prescription for
opioid-based analgesic started to rise.5–7 This was particularly evident with the development of
OxyContin in 1995. Purdue pharma, the producer of OxyContin started aggressively marketing
the drug for the treatment of chronic pain by highlighting the lack of side-effects and false claims
regarding the lack of addiction liability.7,8 Indeed, opioid-based analgesics have shown to be
successful in treating acute and short-term post-operative pain.9 However, chronic administration
of opioids such as OxyContin for the treatment of chronic or persistent pain states has largely been
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ineffective, additionally exposing patients to further develop opioid use disorder overtime.7,8,10
Along with the push for treatment of pain and the marketing of pharmaceutical companies under
the false impression that opioids are safe and devoid of side effects for the management of chronic
pain, the number of opioid prescriptions skyrocketed.5,7 For example, opioid prescriptions from
year 1996 to 1999 rose from 8 million to 11 million, while in 2016 alone over 60 million pain
patients had at least one opioid prescription filled.7,11 In addition,, many clinicians lack the proper
education for evaluation and management of pain patients, as time devoted to pain education in
medical schools is very limited.5 Indeed, the lack of clinical skills in managing chronic pain and
knowledge on the interaction between pain and opioids further contributed to patients misusing
their medication and, in some cases, developing opioid use disorder (OUD).
1.2 Pain and negative affect
Pain is a multifaceted phenomenon composed of sensory and negative emotional-affective
components. In its acute state pain could be an important survival skill as it serves: 1) as a learning
signal to avoid experiences which could cause us harm or 2) protective role for the site of tissue
injury until the affected area has recovered. However, pain can persist even after the injured tissue
has healed, making it even more challenging to treat. As pain persists, the presence of negative
affective states can lead to negative emotional sates such as dysphoria, anhedonia, and anxiety.12–
14

These comorbid disorders can then lead to depression and opioid misuse, consequently

escalating into life threatening events such as suicide attempts or accidental opioid overdoses.10,15
The relationship between the negative affective comorbid disorders and pain is bidirectional, as
the presence of negative emotional states such as depression and anhedonia can exacerbate the
pain experience itself.13 This vicious cycle then keeps getting amplified as pain continues to
persist.
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However, many patients, clinicians and scientists still see pain as solely sensory
experience, which results in suboptimal treatments particularly of chronic or persistent pain
patients where many of the negative affective disorders remain undertreated.5 By not
acknowledging the negative emotional sates in pain, patients are further stigmatized as medication
seekers which leads to amplified suffering. Thus, understanding the processes which mediate
negative affective states in pain is crucial in providing better treatments and improving the quality
of life of pain patients.
1.3 Translational gap between clinical and preclinical pain research
Much of the understanding of pain processing, the underlying physiology and the early
development of novel drugs for treatment of pain can be ascribed to preclinical animal models of
pain. Although, it represents an important translational opportunity the gap in readout of pain-like
behaviors between the preclinical and clinical studies is an issue. This gap arises from the way we
evaluate, assess and measure pain in human patients vs. the way we study and examine pain in
animals used in preclinical studies. Clinical assessment of pain usually consists of qualitative
description of cognitive, emotional and sensory components which are self-reported as the location
of pain, the onset, intensity, and how it interferes with patients’ daily functions.5 In this way, using
numerical and visual rating scales patients mark the level of pain they are experiencing.
On the other hand, in preclinical studies using laboratory animals (mostly rodents), pain
has been mainly studied by measuring nociception, which is detection and processing of noxious
stimuli.16 Common models of chronic and persistent pain involve ligation or compression of nerves
encompassing sciatic nerve (nerve injury) and hindpaw injury or injection of inflammatory agents
such as Complete Freund’s Adjuvant (CFA), respectively.17,18 Although these models do mimic
certain aspects of the pain experience such as hyperalgesia (increased nociceptive response from
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already painful stimulus) and allodynia (nociceptive response results from a stimulus that is usually
not painful), they still do not fully recapitulate human form of nerve injury or persistent
inflammatory pain which normally arise as a consequence of accidental injury or disease state. In
addition, most studies focus only on nociceptive component of pain involving reflexive behavior
to noxious stimuli, which is different than self-reported pain levels in human patients. Nonetheless,
they remain the most used and validated preclinical models of pain in controlled laboratory
settings.
In recent years, there has been an important increase in the number of studies examining
negative affective states in preclinical models of pain. In pain patients’ negative effective states
are expressed in the form of decreased initiation to complete goal-directed tasks, decrease liking
of rewarding stimuli which is representative of anhedonic states, anxiety-like behaviors and
cognitive deficits.19–22 Similar findings have been reported in animal models of pain as well.23–25
Namely, a decrease in motivation for natural and drug rewards using operant behaviors has been
frequently reported in both inflammatory and nerve injury models of pain.23,26 In addition, animals
in pain also exhibit decreased time spent in the center of open field boxes and decreased time spent
in open arms of elevated plus maze, which are both indicative of anxiety like phenotypes.24 On the
other hand, a few studies demonstrate lack of the effect of pain on these behaviors.27 As shown by
the recent metanalysis these discrepancies may arise from differences in the timeline from the
onset of pain at which these behaviors were measure, animal’s previous exposure to stress, strain
of animals tested, as well as models of pain utilized (for example repeated injections of CFA vs. a
single injection).27 Still, conducting behavioral studies which assess affective component of pain
in addition to nociceptive behaviors, while using both male and female animals, are crucial to
further improve translation between pre-clinical and clinical pain studies.
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1.4 Reward processing in the presence of pain
The mesolimbic pathway is a key circuit that integrates both aversive and rewarding
properties of external stimuli. Dopaminergic (DA) transmission in the mesolimbic system, from
the ventral tegmental area (VTA) to the nucleus accumbens (NAc) has long been understood for
its role in the motivated behavior and reward processing.28–31 Previous work has shown that
activation of this pathway is rewarding itself, as it reinforces animal’s behavior which results in
electrical stimulation of VTA DA neurons.32 Similarly, natural rewards and rewarding drugs, such
as opioids, act on the mesolimbic system leading to increase DA release in the NAc, promoting
further reward seeking behaviors.33 On the other hand, depletion of DA or application of DA
receptor antagonists results in decreased approach behaviors and reduction in hedonic responses
to rewarding stimuli.34,35 Interestingly, in animals experiencing inflammatory and nerve injury
pain, motivated behaviors for natural and drug rewards are significantly impaired.23,25,26,36 This
decrease in motivated behaviors is strongly correlated with decreases in the DA signaling in the
mesolimbic pathway.23,26,37 These findings nicely resemble clinical studies which have correlated
pain-induced negative emotional states with a decrease in DA neurotransmission and maladaptive
changes in the function of the NAc and frontal cortex.38,39 In patients experiencing chronic back
pain, a decrease in DA receptor availability in the NAc is observed.39 Taken together these findings
suggest that pain-induced adaptations in reward circuitry are likely to cause alterations in natural
and drug reward seeking behaviors. However, the exact neuronal circuit mechanisms that drive
these maladaptive behaviors are yet to be uncovered.
1.5 The mesolimbic reward pathway
Electrophysiological recordings revealed that mesolimbic DA neurons have two modes of
firing: tonic and phasic.40 Phasic DA activity is defined as transient bursts in firing rate in respond
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to salient stimuli, rewards and cues associated with a reward.40 As such it serves an important role
in reinforcement learning, reward expectancy and motivation.41 While reward and reward-related
cues elicit phasic firing of DA neurons, omission of the reward lead to inhibition of VTA DA
neurons.42–45
While phasic activity leads to bursts firing of VTA DA activity, tonic DA activity provides
sustained DA release thus setting the background level of DA receptor occupancy, contributing to
homeostasis of DA levels, and potentially regulating the intensity of phasic DA activity.33,40
However, it has been reported recently that tonic DA activity also plays a role in signaling the
changing reward value independently of phasic activity which represents rewards of unchanged
values.46 This further illustrates the complexity of VTA DA neurons, and their role in reward
processing, decision-making, response inhibition and motivated behaviors.
It has been recently reported that the nerve injury model of pain decreases spontaneous
firing rate of a subset of VTA DA neurons.47 Furthermore, the activity of VTA DA neuron is highly
controlled by inhibitory GABAergic inputs which play a crucial role in fine tuning reward
behavior. 48,49 The source of GABAergic inputs onto VTA DA neurons arise from the rostromedial
tegmental nucleus (RMTg), NAc, ventral pallidum (VP), and bed nucleus of stria terminalis
(BNST), among others, and make up a majority of the synaptic input.50–52 Furthermore, RMTg
GABAergic inputs are highly controlled by the  opioid receptor system which is downregulated
in the presence of pain.23,49,53 Although both NAc and VP represent a substantial source of GABA
input onto the VTA DA neurons, DAMGO application onto RMTg-VTA GABAergic inputs exerts
even higher magnitude of DA neuron disinhibition.49 In addition, in vivo morphine treatment
results in tolerance to the inhibition of RMTg inputs, but not local VTA GABA interneurons or
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NAc GABA inputs.49 While RMTg is a highly opioid-sensitive GABA input onto the VTA DA
neurons, its role in modulating inhibition of DA neurons in pain has not been assessed.
Considering the implication of DA signaling in pain-induced affective states and the
inhibitory control exerted by GABAergic inputs onto the VTA DA neurons, it is of great
importance to dissect how pain modulates these neural circuits and alters GABA- and DApathways (Figure 1).

Hippo

PFC

Hippo

PFC

- GABA neurons
- DA neurons
NAc

NAc

VTA
VP

- µ opioid receptor
VTA
VP

RMTg

RMTg

GABA
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Figure 1. Simplified proposed circuitry for mediating motivational deficits and altered dopamine signaling in the presence of pain. Persistent
pain causes dysregulation of µ opioid receptor function at the VTA GABA projecting neurons/interneurons causing stronger inhibitor of VTA DA
neurons and subsequent decrease of DA release in the NAc

Figure 1. Simplified proposed circuitry for mediating motivational deficits and altered DA signaling in the
presence of pain. Persistent pain causes dysregulation of MORs function at the GABA terminals projecting to the
VTA, leading to stronger inhibition of VTA DA neurons and subsequent decrease in DA release.

1.6 Endogenous opioid receptor system and pain
Opioid receptor systems which are present ubiquitously throughout the central and
peripheral nervous system, consists of  (MOR), kappa (KOR), delta (DOR) and nociceptin (NOR)
opioid receptors all of them being G protein-coupled receptors (GPCRs).54 These receptors are
stimulated by endogenous opioid peptides  endorphins, dynorphins, enkephalins and nociceptin.
Under normal physiological states opioid receptor systems maintain homeostasis and alterations
in the activity of these systems is largely state dependent. When activated, opioid receptor systems
regulate reward processing, mood, motivation and produce pain relieving effects.8,55,56
 opioid receptors (MOR) within the VTA, play a critical role in mediating the rewarding
effects and motivation for palatable foods and opioid drugs.55 Microinjection of MOR agonists
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such as DAMGO or morphine into the VTA induces conditioned place preference, increases food
intake and food seeking.57–60 In contrast, microinjection of the selective MOR antagonists in the
VTA decreases consumption of ethanol and palatable foods.58 These effects are mediated through
inhibition of GABA release as MOR are a family of inhibitory GPCRs expressed presynaptically
on the GABAergic afferents/interneurons.61 Their activation results in disinhibition of DA neurons
and increased DA neurotransmission. Interestingly MOR systems are not only necessary for the
rewarding effects of opioid such as morphine and fentanyl but also for their analgesic properties.8
Intriguingly, opioid evoked DA release is attenuated in presence of inflammatory and nerve injury
pain.23,36 This attenuation is overcome by increasing the concentration of opioid by 10-fold.
Similar effects are seen in the motivated behavior for opioid rewards, where increasing the dose
of opioid prevents pain induced decrease in motivation.23 Thus, downregulation of the MOR
system in the presence of pain could be the likely reason of why opioid drugs are not very effective
in persistent pain conditions, potentially putting pain patients at risk of developing opioid use
disorder.
KOR agonists on the other hand are aversive. KORs are inhibitory GPCRs which when
activated inhibit DA release at the terminal projections in the NAc.62 In contrast to MORs, KORs
stimulation lead to dysphoria and “anti-reward” effects.63–65 Even though KOR agonists are potent
analgesics, KOR activation can lead to hallucinogenic effects, impaired stress-coping skills and
decreased reinforcing properties of stimuli, limiting their use as a medicinal drug.63,65–68 While
MOR system is downregulated in pain, previous studies have shown that KOR system is
upregulated in pain thus at least in part mediating negative affective states.25,69,70 Particularly,
recent studies show that both inflammatory and nerve injury pain recruit the KOR system in the
NAc to drive aversive states and decreased motivation for natural rewards.25,70 Since this system
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is upregulated in pain leading to negative emotional states, KOR antagonists have the potential to
serve as medications to alleviate negative affective states in pain thus reducing the likelihood of
comorbid psychiatric disorders.71,72
DOR agonists represent another group of pain relieving drugs. Unlike MOR, the DOR
system is not essential for rewarding properties of opioids, and stimulation of this system exhibits
fewer side effects.73,74 Their anxiolytic properties are desirable for improving mood states in
chronic pain state; however, they lack nociceptive effects in acute pain models in comparison to
MOR agonists.8,75 Additionally, activation of DORs can lead to convulsions which limits their use
in clinic.76 Further studies are necessary to determine the effects of pain on the function and
regulation of DOR system.
Lastly, the NOR system is the most recently discovered endogenous opioid system, and
thus the least characterized.77 They are expressed in areas of the brain mediating pain, memory
and reward and represent an exciting avenue of pain and reward research. They are known to
modulate anxiety, food intake, motivation and opioid reward.78–81 Their role in pain and negative
affect remains to be further elucidate.
1.7 Improving pain management
Current treatments for pain include opioids, which despite their analgesic properties exert
high misuse liability especially when administered chronically and could lead to overdose deaths
induced by respiratory depression.15,22,72 As discussed above, chronic pain patients in addition to
sensory disturbance also experience psychiatric comorbidities such as depression, anhedonia and
anxiety, which makes them more susceptible to misuse their opioid medication. Thus, creating
potent pain-relieving drugs which are devoid of misuse potential and respiratory side effects and
successful in treating negative affective states are an important area of drug development research.
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One of the approaches in uncovering novel analgesics that has sparked interest recently is
creating biased agonists of opioid receptors.82,83 GPCRs such as MOR, KOR and DOR when
bound to the agonist initiate a sequence of signaling cascades and convey their intracellular signal
though interaction with G proteins. GPCRs can also couple to non-G proteins such as -arrestins
initiating additional signaling cascades.56 In pain and addiction research it has been postulated that
these different signaling cascades of opioid receptors mediate different behavioral outcomes. For
example, MOR agonist induced activation of -arrestin pathway is sufficient to produce tolerance,
constipation and respiratory depression.84,85 In this case creating biased agonist that will
preferentially activate G protein signaling cascade with little to none -arrestin pathway activation
would be desirable. However, some of the studies have reported that respiratory depression and
tolerance continue to be present even in -arrestin knockout animals.86 Further research is
necessary to really delineate which signaling cascades are mediating physiological and behavioral
effects and whether they are dependent on the brain area where these receptors are expressed.
Another, possibility is to utilize peripherally restricted opioids for pain management.47,87
While this approach has a potential to avoid abuse (misuse) liability of opioid medications, it is
likely that in the presence of chronic pain peripherally restricted opioids may fall short in managing
centrally mediated negative affective comorbidities. In such case, they could be potentially given
in combination with KOR antagonist which could help alleviate negative affective states.
However, it would be important to assess between drug interactions and any undesirable effects,
as well as their efficacy in managing different forms of pain.
Besides opioid medications, additional treatments could be useful in managing chronic and
persistent pain such as nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, local
anesthetics, anticonvulsants, and, in certain pain models such as cancer pain, cannabinoids.88–91
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Their efficacy in pain management could be further bolstered by non-pharmacological therapies
such as physical therapy, cognitive-behavioral therapy, meditations strategies and therapeutic
exercising.38,92 Despite the continuous efforts to developing better pain management approaches
we are still needing medications which lack dangerous side effects. Thus, it is crucial to advance
basic research uncovering the effects of different pain models on adaptations within central and
peripheral nervous system, and how these adaptations alter nociception and negative affect.
1.8 The Opioid crisis
OUD of heroin, prescription pain relievers and synthetic opioids such as fentanyl represents
major economic, social and public health crisis, with economic burden estimated at 80 billion
dollars a year.4,93 OUD encompasses dependence, abuse, misuse and addiction to opioid drugs
which can be described by compulsion to seek the drug, inability to control drug intake and
emergence of negative affective states such as dysphoria and irritability when drug taking is
ceased.55,94–96 In addition, OUD is a relapsing disorder and thus represents a life-long battle for
people suffering from it. Increase in prescription opioid rates in the 90’s is in part responsible for
devastating numbers of people suffering from OUD.7,97 With the increase of prescription opioids,
the opioid overdose began to rise. In 2019 alone 50 000 people died from opioid-induced
overdoses, with many more suffering from OUD.93
While minimizing the prescription opioid rates may seem like a potential solution to this
problem, it causes further damage as it leaves pain patients who have already become depended
on their medication to look for opioid drugs elsewhere. This is highly illustrated by the fact that
around 80 percent of people who use heroin have first misused prescription opioids.4,98 Thus, an
important aspect of managing current opioid epidemic is finding alternative medications for pain,
slowly decreasing the prescription opioid rates where possible, providing current OUD patient
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with maintenance strategies which will help them wean of opioid drugs, and lastly develop novel
medications to prevent relapse rates.
1.9 Modeling human-like drug-taking behavior in rodents
In order to develop better strategies for managing OUD we need to understand what
circuity mechanisms are mediating different aspects of drug-taking cycles. To answer these
questions scientists often times, turn to operant or classical conditioning, two important concepts
in behavioral neuroscience.99,100 Both of these concepts involve some form of learning in relation
to a rewarding stimulus. In classical conditioning, first described by Russian psychologist Ivan
Pavlov, previously neutral stimulus, such as sound of the bell, is paired with unconditioned
stimulus (US), such as taste of the food.101,102 This pairing than results in salivating which
represents unconditioned response. After multiple associations between the neutral stimulus and
US, the sound of the bell alone evokes salivating. This is known as conditioned response (CR).
This kind of automated behavioral response is involved in habit formation, learning and memory.
Conditioned place preference test (CPP) is one of the classical conditioning tests. In this task one
part of behavioral box with distinct contextual cues (neutral stimulus) is paired with US such as
natural or drug rewards, while opposite side of the box is paired with non-rewarding stimulus such
as saline.103 On the test day the animal is free to explore both sides of the box. If the pairing of the
context and the drug is rewarding the animal will spend more time in the context in which reward
was given creating a preference for that side. If the paring between drug and context is aversive
the animal will avoid the context in which drug was given creating conditioned place aversion
(CPA).
While reward attainment in Pavlovian conditioning is non-contingent as rewards are
usually administered by experimenter, in the operant conditioning paradigm the animal performs

13

the action that results in the reward delivery (in a contingent fashion), making it more suitable to
model voluntary human-like drug taking.104 Operant (or instrumental) conditioning was first
described using operant chambers (“Skinner box”) by American psychologist B.F. Skinner.105 In
this paradigm, performed behavior is reinforced by reward delivery or to avoid punishment. For
example, the animal voluntarily choses to perform an action such a lever press to receive a reward
like sucrose pellet or drug reward or avoid punishment such as electric shock. The reward
availability or delivery can be associated with cues or context of the box, allowing researchers to
investigate reward-seeking behavior in the absence of the reward by presenting the cues associated
with the reward availability/delivery. In addition, the number of lever presses that is required to
obtain a reward can be altered such that motivation to obtain that reward is measured. This
experimental approach has successfully recapitulated acquisition and escalation of drug taking
behavior using short- and long-term access paradigms, abstinence and extinction of drug seeking,
and incubation of drug craving or relapse.106–109
The ability to form the association between the context in which the drug was taken and
rewarding properties of the drug plays a key role in relapse. Thus, uncovering the long-term
maladaptive changes in the brain circuitry upon repeated drug intake are crucial in developing
strategies to prevent relapse behaviors which can ultimately lead to overdose deaths.
1.10

Neurocircuitry of OUD
OUD involves maladaptive long-term changes in multiple brain areas mediating binge or

intoxication of drug intake, physical withdrawal and negative affect, and craving.94–96,110,111
Binge intake of opioid drugs involves areas of the brain which are mediating habit
formation and reinforcement., such as VTA, NAc, central nucleus of amygdala (CeA) and VP. For
example, microinjections of opioids in the VTA and NAc result in conditioned place preference
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(CPP) and increased DA release.23,37 In addition, using intracranial self-administration animals
will repeatedly perform behavior which results in direct infusions of opioids in the VTA and
NAc.112–115 While opioid administration increases VTA-NAc neurotransmission, morphine
administration reduces inhibitory function of CeA GABAergic synapses.116 Furthermore,
stimulation of GABA receptors in the CeA inhibits morphine CPP.116 One of the major outputs of
NAc is VP which is another key area underlying reward processing. Indeed, lesions in this bran
area block motivation for heroin, while injections of morphine in the VP decrease ethanol intake,
thus making this area important modulator of drug intake as well.117,118
Another important aspect of OUD is withdrawal and negative affective states which arise
when rewarding and hedonic effects of opioid start to wear off. These negative withdrawal states
are characterized by fatigue, physical sickness, decreased motivation for non-drug rewards,
anxiety and anhedonia.119 Negative withdrawal states lead to adaptations in the brain areas known
to mediate stress, aversion and negative reinforcement (behavioral response reinforced by avoiding
aversive stimuli/state). It has been shown that a suppression in the mesolimbic VTA-NAc DA
system is associated with withdrawal states of OUD.120 This decrease in DA neurotransmission in
the NAc is associated with hyperactivity of KOR system and increased dynorphin release, leading
to anhedonic states.121 An additional area mediating stress and aversion is the bed nucleus of stria
terminals (BNST). Intracranial injections of noradrenergic antagonists into BNST blocks CPA
induced by opioid withdrawal.122 Lastly, the stress related neuropeptide corticotropin releasing
factor (CRF) is upregulated during withdrawal, and administration of CRF receptor agonists
decreased opioid withdrawal CPA.123,124
Even after withdrawal symptoms and negative affective states have subsided following a
period of abstinence from drug use, drug craving can still persist and lead to reinstatement (relapse)
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of drug seeking behavior. Drug-craving and drug-seeking can be triggered by different stimuli,
such as re-exposure to the drug or context/cues associated with the previous drug intake, presence
of stressful events or the emergence of negative emotional states. Animal studies have
demonstrated that drug-primed reinstatement of drug seeking is mediated via NAc and VP circuit,
while basolateral amygdala (BLA) and hippocampus are critical for cue-induced reinstatement.
For example, BLA plays a crucial role in assigning motivational salience to neutral stimuli paired
with opioid withdrawal.125,126 These stimuli can then act as triggers for drug seeking. In addition,
numerous studies indicate that glutamatergic transmission in the hippocampus is crucial for the
formation of the learned associations between the rewarding effects of opioids and the context in
which they are given.127–130 Additionally, opioid withdrawal following repeated morphine
administration is associated with enhancement of hippocampal plasticity and hippocampus
dependent learning and memory.127,131 This suggests that associations between context and drug
withdrawal symptoms could also lead to future drug-seeking behavior to avoid negative
withdrawal symptoms.
Long term maintenance of associations between the reinforcing effects of the drug and the
environment in which they are administered are a leading cause of relapse. Considering the role of
hippocampus in the formation of memories between the rewarding properties of opioids the
context in which they are given, it is of great interest to assess to role of this area in reinstatement
of drug-seeking behavior.
1.11

Dorsal hippocampus and reward related memories
The hippocampus is a part of the limbic system which plays an important role in mediating

learning, memory and spatial navigation. Indeed, the vast majority of both clinical and preclinical
research have demonstrated that lesions in this area lead to learning deficits and memory loss
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(amnesia).132,133 Since the time of Ramon y Cajal, it has been suggested that brain stores memories
by creating stronger connections between neurons that activate simultaneously, and Donald Heb
in 1948 formalized this theory also known as Hebbian theory.134,135 This theory states that the
information is stored in the neuronal connections between neuronal networks, and that repetitive
correlated activation of pre- and post-synaptic neuron leads to strengthening of these connections
(synapses). Strengthening of synaptic connections is also known as long-term potentiation (LTP)
which is a form of brain plasticity and has been well studies in hippocampus.136,137 Through this
process we are able to develop a memory in response to external stimuli, which is the basis of
associative learning also known as classical conditioning.
In rodents, the hippocampus is divided into two functionally distinct areas, dorsal
hippocampus and ventral hippocampus.138,139 It has been postulated that the dorsal hippocampus
has a primary role in cognition and spatial memory processing, while ventral hippocampus is
important in the processing of emotion, stress and affective memory.140,141 These two sub-areas
also differ in their connectivity with other brain areas, in terms of gene expression profiles, and
cellular organization.139,142,143 While no formal division between dorsal and ventral hippocampus
exists in humans, the function and structure of these two areas resemble septal and temporal
portions of human brain.132
Considering its role in associative learning, the hippocampus represents an important area
in processing learned associations between the cues and drug rewards which are particularly
important in driving reinstatement of drug seeking.
1.12

Conclusions
Our affective emotional states and the ability to form memories in large contribute to the

quality of our lives. However, in disease states these functions could be impaired or become
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maladaptive, interfering with the normal daily functions and decreasing the quality of patient’s
life. This dissertation will assess the neuronal circuit and the mechanism underlying negative
affective states in persistent inflammatory pain and will dissect the neuronal circuitry mediating
contextual cue-induced reinstatement of drug seeking. These two processes known as negative
affective component of pain and relapse of drug-seeking behavior are thought to be the key
contributors to the current pain and opioid crisis in the USA. The goal of this work is to further
uncover which brain circuits are involved in mediating these behaviors in preclinical models of
pain and OUD.
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Chapter 2
Pain decreases ventral tegmental area dopamine neuron
excitability to drive negative affective states

This chapter contains previously unpublished data:
MARKOVIC T., PEDERSEN C., MASSALY N., VACHEZ Y., MURPHY C., ABIRAMAN K.,
RUYLE B., SHIN H., GARCIA J., ALVAREZ V., BRUCHAS M., CREED M., MORÓN J.A.,
Pain induces somatic adaptations in Ventral Tegmental Area Dopamine neurons to drive
anhedonia-like behavior. Nature Neuroscience, under revision.
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2.1 Abstract
The persistence of negative affect in pain leads to co-morbid symptoms, such as anhedonia
and depression, representing a major health issue in the US. However, the neuronal circuitry and
contribution of specific cellular populations underlying these behavioral adaptations remains
unknown. A common characteristic of negative affect is a decrease in motivation to initiate and
complete goal-directed behavior. We report that persistent pain decreases the activity of ventral
tegmental area (VTA) dopamine (DA) neurons which are critical mediators of motivational states.
Furthermore, we demonstrate that decreased activity of DA neurons is associated with reduced
motivation for natural rewards, consistent with anhedonia-like behavior. Lastly, selective
activation of VTA DA neurons is sufficient to restore baseline motivation and hedonic responses
for natural rewards. Our findings reveal that somatic adaptations within VTA DA neurons underlie
pain-induced anhedonia-like behavior.
.
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2.2 Introduction
Pain is a multifaceted experience composed of sensory and emotional-affective
components.1,2 As pain persists, the presence of negative affective states can lead to the
development of negative emotional states such as anhedonia, anxiety, and depression. 2–5 While
current pharmacological therapies provide high potency in alleviating sensory disturbances, the
negative affective states accompanying pain remain undertreated.3–6
Emerging evidence from human and preclinical studies show deficits in emotional decision
making, reward evaluation and reward seeking, or motivation in pain states.7,8 These alterations in
reward processing and decreased motivation represent key components of pain-induced negative
affective states that can lead to the development of anhedonia and depression.5,7,9–11 Uncovering
the neuronal circuitry mediating these pain-induced negative affective states may provide new
opportunities to develop safer therapies for pain treatment and limit the development of co-morbid
disorders.
The mesolimbic reward pathway, composed of dopaminergic (DA) input from the ventral
tegmental area (VTA) projecting to the nucleus accumbens (NAc), has a prominent role in reward
processing and motivated behavior.12–16 Clinical studies using neuroimaging approaches have
revealed decrease in the magnitude of DA release and DA receptor activation in the NAc in patients
experiencing pain.17,18 This result is consistent with preclinical evidence demonstrating a decrease
in evoked DA release in the NAc in both inflammatory and neuropathic pain.19,20 Furthermore, a
recent study reports that pain-induced negative affect is associated with adaptations in the
dynorphin neurons in the NAc, which are under potent control of DA.21 While these alterations in
DA transmission in the NAc may in part explain the impaired motivated responses to natural and
drug rewards observed in rodents experiencing pain19–23, the exact mechanisms by which VTA
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DA neurons are mediating pain-induced adaptations in the mesolimbic pathway remain to be
elucidated.
Using the complementary approaches of in vivo fiber photometry and patch-clamp
electrophysiology, we report that reduced motivation induced by pain is associated with decreased
excitability and diminished activity of VTA DA neurons. This decrease in VTA DA neuron
excitability is associated with increased inhibitory drive onto them. Furthermore, we report that
enhancing activity of NAc-projecting DA neurons in the VTA using chemogenetics is sufficient
to overcome pain-induced reduction in motivated behavior. We also demonstrate that the decrease
in sucrose consumption induced by the presence of pain can be overcome by increasing the
concentration of the sucrose reward, further suggesting impaired hedonic responses in pain.
Overall, the results generated in this study provide key evidence that the experience of pain
decreases activity and excitability of VTA DA neurons, and that blunted VTA DA activity then
contributes to pain-induced negative affective states. Our findings represent a crucial step in
understanding the neural mechanisms underlying the emotional component of pain and may
provide novel targets for the treatment of pain-induced negative affect.
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2.3 Materials and methods
Animals:
All procedures were approved by Washington University and the National Institute on
Alcohol Abuse and Alcoholism (NIAAA) Animal Care and Use Committee in accordance with
the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Adult
male and female Long Evans Wild Type and TH-cre rats (250-350g), and DATIRES-cre mice crossed
with Cre driven expression of ChR2 mice (AiCop4) were used for this study. All animals for
behavioral experiments were 8 to 10 weeks old at the beginning of the experiments. Animals used
for patch-clamp electrophysiology were 3.5 weeks old. Animals were group housed with two to
three animals per cage on a 12/12 hours dark/light cycle (lights on at 7:00 AM) and acclimated to
the animal facility holding rooms for at least 7 days before any manipulation. All experiments
were performed during the light cycle. Rats received food and water ad libitum until 2 days prior
to starting the behavioral studies, when food restriction (16 g of rat chow per day) started and
continued until the end of the experiments. Mice received food and water ad libitum throughout
the entire experimental procedure.
Surgeries:
All surgeries were performed under isoflurane (2.5/3 MAC) anesthesia using appropriate
sterile aseptic techniques.
Intra cerebral injections:
For chemogenetic activation of VTA DA neurons and fiber photometry recordings of VTA
DA neuron activity, TH-cre rats were bilaterally injected with either AAV5-hSyn-DIOhM3D(Gq)-mCherry, AAV5-Ef1a-DIO-mCherry, AAV-DJ-EF1a-DIO-GcaMP6s (all viruses
injected at 1.5-2.5x1012 transducing units per ml – 0.5μl per side, Addgene), and/or implanted with
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fiber optic (Doric lenses) in the VTA (stereotaxic coordinates for viral injections from Bregma:
A/P = -5.3mm, M/L = ± 0.7mm, D/V = − 8mm; stereotaxic coordinates for optic fiber from
Bregma: A/P = -5.3mm, M/L = ± 0.7mm, D/V = -7.8mm from the skull surface, World Precision
Instruments). The optic fiber implant was secured to the skull using three sterile bone screws and
a dental cement head-cap (Lang Dental).
For chemogenetic activation of NAc projecting VTA DA terminals in addition to
DREADD injections animals received bilateral intra-NAc cannula implants (stereotaxic
coordinates for cannula implant from Bregma: A/P = +1.2mm, M/L= -0.8MM, D/V= -6.0mm from
the skull surface with injectors extending 1mm past the tip of the cannula) for the local delivery of
either aCSF or CNO.
For combined chemogenetics experiments wild type (WT) rats were bilaterally injected
with retrograde Canine AdenoVirus CAV2-cre (2.14x1012 transducing units per ml – 0.5μl per
side, The Institute of Molecular Genetics of Montpellier) in the NAc (stereotaxic coordinates for
viral injections from Bregma: A/P = +1.2mm, M/L= -0.8MM, D/V= -7.0mm from the skull
surface) and either AAV5-hSyn-DIO-hM3D(Gq)-mCherry or AAV5-Ef1a-DIO-mCherry in the
VTA. Following viral injections, the incision was closed using sterile stainless steel wound clips
(Autoclip, Braintree Scientific, Inc).
To avoid post-surgical complications and minimize pain, animals received a daily
subcutaneous (s.c.) injection of 8mg/kg enrofloxacin and 5mg/kg carprofen solution for 2
consecutive days together with complementary carprofen chewable tablets. Behavioral
experiments were started either 3 or 5 weeks after intracerebral injections to allow for maximal
viral expression at the time of testing.
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Complete Freund’s Adjuvant (CFA) injections:
Animals were sedated using isoflurane anesthesia. Once appropriate sedation was
achieved, as determined by lack of reflex during toe-pinch, rats and mice were injected in the right
hindpaw with 200 μl or 50 μl of CFA solution (Thermo Fisher), respectively. Saline injected
animals served as controls. Animals’ general behavior (feeding, drinking, locomotion) was
monitored throughout the duration of experiments.
Ex vivo fast-scan cyclic voltammetry (FSCV):
Mice were anesthetized with isoflurane and euthanized by decapitation. Brains were sliced
in sagittal orientation at 240 µm thickness with a vibratome (VT-1200S Leica) in an ice-cold
cutting solution containing (in mM) 225 sucrose, 13.9 NaCl, 26.2 NaHCO 3, 1 NaH2PO4, 1.25
glucose, 2.5 KCl, 0.1 CaCl2, 4.9 MgCl2, and 3 kynurenic acid. Slices were incubated for 20 min at
33 °C in artificial cerebrospinal fluid (ACSF) containing (in mM) 124 NaCl, 1 NaH 2PO4, 2.5 KCl,
1.3 MgCl2, 2.5 CaCl2, 20 glucose, 26.2 NaHCO3, 0.4 ascorbic acid, and maintained at room
temperature prior to recordings. Slices were placed in a submerged chamber perfused at 2 ml/min
with ACSF at 32 °C using an in-line heater (Harvard Apparatus). Cylindrical carbon-fiber
electrodes (CFEs) were prepared with T650 fibers (6 μm diameter, ~150 μm of exposed fiber)
inserted into a glass pipette. Before use, the CFEs were conditioned with a 8 ms long triangular
voltage ramp (-0.4 to +1.2 and back to -0.4 V versus Ag/AgCl reference at 4 V/s) delivered every
15 ms. CFEs showing current above 1.8 µA or below 1.0 µA in response to the voltage ramp
around 0.6 V were discarded.
DA transients were recorded using the same triangular voltage ramp delivered every 100
ms in the NAcSh area (A/P: + 1.30mm, M/L: ± 0.5mm, D/V: –4.75mm), and evoked by either
monopolar electrical stimulation through an ACSF filled glass pipette placed by passing

40

rectangular pulse of 100–250 μA at 0.2 ms duration (Cygnus Technology Inc.) or brief light pulse
(1 or 2 ms) through using an optical fiber (200 µm/0.22 NA) connected to a 470 nm LED (2 mW;
ThorLabs) delivered every 2 min. Data were collected with a modified electrochemical headstage
(CB-7B/EC retrofit with 5 MΩ resistor) using a Multiclamp 700B amplifier (Molecular Devices)
after being low-pass filtered at 10 kHz and digitized at 100 kHz using custom-written software in
Igor Pro (Wavemetrics) running mafPC software (courtesy of M.A. Xu-Friedman). Customwritten analysis software in Igor Pro was used for analysis. Decay time constants were obtained
with a single exponential fit of the derivative of the falling phase of DA transient curve.
Patch-clamp electrophysiology:
Visualized whole-cell recording techniques were used to measure holding and synaptic
responses of DA neurons in the VTA. Currents were amplified, low-pass filtered at 4 kHz, and
digitized at 10 kHz. Recordings were performed in whole cell configuration with the patch pipette
internal solution containing (in mM): 130 potassium gluconate, 10 phosphocreatine disodium salt,
4 MgCl2, 3,4 Na2ATP, 0,1 Na3GTP, 1,1 EGTA, 5 HEPES. All recordings were performed in
dopamine neurons identified by 1) a cellular capacitance > 30 pF, 2) spontaneous firing below 5
Hz, and 3) the presence of large hyperpolarization-activated inward current, /h. To ascertain the
presence of /h currents, neurons were voltage clamped at -60 mV, and the response to five
hyperpolarizing voltage steps (250 ms, -25 to -125 mV in increments of -25 pA) were measured.
The spontaneous activity and the responses to current injections were made in current-clamp
configuration. Spontaneous firing rate and resting membrane potential was recorded for 5 minutes,
in 5 trials of 60 seconds. To generate an input-output curve of neuronal excitability, 200 ms current
steps were injected in increments of 10 pA from -50 to 200 pA and the numbers of spikes were
quantified for each step. Rheobase was determined by injecting 100 ms ramps of increasing current
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(0 — 180 pA) and measuring the current where the first action potential was observed. To assess
the impact of inhibition on DA neuron excitability, experiments were first conducted in the
presence of glutamate receptor antagonist kynurenic acid (2 mM), and again after artificial
cerebrospinal fluid (aCSF) containing GABAA receptor antagonist picrotoxin (100 μM) was
washed on. Spontaneous inhibitory postsynaptic currents (sIPSCs) were recorded in the presence
of kynurenic acid (2 mM). VTA DA neurons were voltage clamped at -60 mV with the patch
pipette internal solution containing (in mM): 100 KCl, 30 potassium gluconate, 4 MgCl2, 10
phosphocreatine disodium salt, 3.4 Na2ATP, 0.1 Na3GTP, 1.1 EGTA, and 5 HEPES. Recordings
were excluded if the series resistance or noise level varied by more than 25% over the course of
recordings.
Operant conditioning:
Rat sucrose self-administration was conducted using operant-conditioning chambers (Med
Associates) equipped with two retractable levers positioned on the right-hand wall and a food
magazine connected to a food pellet dispenser between them. Two cue lights were positioned
above the levers, and one house light was positioned on the top left-hand wall. During selfadministration sessions both levers (correct and incorrect) were extended out with white cue light
turned on only above active lever. Presses on the correct lever resulted in sucrose pellet delivery
and a 20 s time-out period during which correct and incorrect lever were retracted, and cue light
above correct lever was turned off. Presses on the inactive lever did not result in any changes in
the environment.
Three to five weeks after the surgical procedure (chemogenetic activation of VTA DA
neurons, chemogenetic activation of VTA-NAc pathway and photometry, respectively), animals
were trained to self-administer sucrose pellets as follows. First, animals were placed in operant
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boxes under fixed ratio (FR) 1 schedule of reinforcement for sucrose self-administration for 2
hours or until the rat reached a maximum of 60 rewards. Once the animals completed 3 consecutive
daily sessions obtaining 60 rewards, they were then exposed to 3 FR2 sessions followed by 3 FR5
sessions. On the following day, animals were gently placed back in the self-administration
enclosures and were given access to sucrose during a two-hour session on a progressive ratio (PR)
schedule of reinforcement, during which the number of correct lever presses to receive the
following reward increases exponentially (5 × e(0.2 × infusion number) – 5 rounded to the nearest integer
resulting in the following PR steps: 1, 2, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95…). Following
the baseline PR session, animals received an injection of either saline or a CFA in the right
hindpaw. Forty-eight hours after inflammatory pain induction, rats underwent a second two-hour
PR session. For chemogenetic activation of VTA DA neurons, or the VTA-NAc pathway,
clozapine-N-oxide (CNO 1mg.kg-1 s.c, Sigma) was administered 20 mins prior to starting the
second PR session.
For chemogenetic activation of VTA-NAcSh projecting DA terminals 250ul/side intraNAcSh microinjections aCSF (on PR1) and aCSF or 1mM CNO (on PR2) were delivered over 5
minutes using Harvard Pump 11 Elite Series. Injectors were left in place for additional 2.5 minutes
to allow for diffusion of the injected solution. Fifteen minutes after the start of intra-NAcSh
injection, animals were placed in the boxes and PR sessions were started.
Open field test for locomotor activity:
Open field test was performed in square enclosures (60 X 60 cm) within sound attenuated
room at 23 C room temperature. Animals underwent three 5 minutes habituation sessions
followed by 30 minutes baseline session. Following baseline session animals received either CFA
or saline injections in the paw. Forty-eight hours after the intraplanar injections s.c injections of
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either CNO 1mg.kg-1 or saline were administered. Second 30 minutes testing session in open field
started 20 minutes after the s.c. injections. At the beginning of each session animals were placed
in the center of the open field and total distance traveled was recorded and analyzed using
AnyMaze behavioral tracking software (Stoelting Co.).
Hargreaves plantar test for thermal sensitivity:
To assess thermal hyperalgesia induced by CFA injection we used the Hargreaves Plantar
Test (IITC Life Science). Animals were placed in Plexiglas boxes on top of a glass surface. After
15 minutes of habituation, a heat source was applied on the plantar surface of the right hindpaw,
and the latency of paw withdrawal from the heat stimulus was recorded. Animals underwent 3
habituation sessions prior to testing. Testing sessions consisted of four measurements with at least
a 5 min interval between trials. Latency was determined by averaging all four trials per each testing
session.
For chemogenetic experiments, thermal hyperalgesia was assessed 1 hour prior to PR1
(baseline) and PR2 (CFA/saline) sessions. To investigate the sufficiency of chemogenetic
activation/silencing of neuronal pathway in hyperalgesic states during PR tests, an additional
Hargreaves session was performed on the day following PR2 session 20 minutes after saline or
CNO s.c. injection, or 15 minutes after aCSF or CNO intra-NAcSh microinjections.
For locomotor experiments thermal hyperalgesia was assessed 1 hour prior to baseline and
testing (CFA/saline) sessions. An additional Hargreaves session was performed on the day
following locomotor testing session 20 minutes after saline or CNO s.c. injection to assure that
chemogenetic activation of VTA DA neurons does not alter CFA induced hyperalgesia in these
animals. For photometry studies, thermal hyperalgesia was tested 1 hour prior to any PR sessions.
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Lastly, for the two-bottle choice experiments (see below) thermal hyperalgesia was assessed 1
hour prior to baseline and post-CFA/saline testing sessions.
Orofacial reactivity:
Animals were water restricted as in the two-bottle choice experiment. Rats were
individually placed in a cage with no bedding and free access to a solution (water, 5%, 30%, or
60% sucrose) placed in a petri dish on the floor. Rats were filmed at 100 frames/s during drinking
bouts. Consummatory and hedonic tongue protrusions from the three first bouts were scored
offline. Hedonic protrusions were defined as any event where the tongue was extended out of the
mouth but did not make contact with sucrose solution, in contrast to consummatory protrusions.
For each rat, only one solution was tested per day and the order of solutions was counterbalanced
within rats. In a separate session, rats were given free access to 0.05% quinine and aversive gapes
were scored.
Two-bottle choice:
For the two-bottle choice studies, animals were water-restricted to four hours of water
access following the experimental session. For testing sessions, rats were individually placed in a
cage with no bedding and free access to either water or sucrose solutions placed on top of the wire
rack covering the cage. Water and sucrose solution bottle placement (right or left) was
counterbalanced. After 4 daily 1-hour habituation sessions during which animals were exposed to
water and a 5% sucrose solution, a baseline measurement of water and sucrose (5%, 30% or 60%)
consumption was obtained. Immediately after the baseline session, CFA was injected in animal’s
hindpaw as described above. Saline injection was used as a control. Forty-eight hours after
intraplantar injection, another test was conducted to determine the impact of pain on water and
sucrose solution consumption.
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For chemogenetic studies, CNO (1mg.kg-1 s.c.) was injected 20 minutes prior to starting a
two-bottle choice testing session. All measurements for water and sucrose consumption were
recorded as volume (ml) and amount (g) of liquid consumed.
Immunohistochemistry:
Following each behavioral experiment, rats were trans-cardially perfused with phosphate
buffered saline (PBS) followed by 4% paraformaldehyde (PFA). For cFos experiments rats were
perfused 90 minutes following the s.c. injection of either 1mg.kg-1 CNO or saline to allow for
maximal neuronal activation. Brains were collected and kept at 4ºC for 24h in 4% PFA for postfixation, followed by 72h incubation in 30% sucrose solution. Isopentane was used to flash freeze
brain tissue which was consequently cut in 40 µm coronal slices using a cryostat (Leica CM 1950).
Free-floating sections containing VTA were washed in PBS and blocked with Normal Donkey
Serum (Millipore, S30) and 0.3% Triton-0.01 M PBS (PBS-T) and incubated overnight in 3%
normal donkey serum and 0.3% PBS-T containing TH (1:2,000, mouse anti-TH, MAB318,
Millipore), mCherry (1:500; rabbit anti- mCherry, ab167453, Abcam; or chicken anti-mCherry for
cFos experiments, ab205402 Abcam), and/or cFos (1:2,000, rabbit anti-cFos, ab190289, Abcam).
The following day, sections were again rinsed with PBS and then incubated (2 hr) with the
appropriate secondary antibodies (Jackson ImmunoResearch).
A Leica DMR microscope was used to process images (5x,10x and/or 20x magnification)
of viral expression. Image J software was used to manually quantify the number of labeled cells
for combined chemogenetics experiments and cFos activation. For combined chemogenetic
quantification VTA images were taken at 10x magnification and neuronal counts were performed
in all VTA slices expressing m-Cherry from -4.80 AP to -6.12 AP. For cFos quantification VTA
images were taken at 20x magnification and 3 VTA slices of equivalent distance from bregma
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between -4.80 AP to -6.12 AP were quantified per animal. Cell counts were done by two
independent researchers that were blinded to experimental results.
Photometry Acquisition:
For fiber photometry studies, rats were food restricted and trained in operant conditioning
(Med Associates Inc.) as described in behavioral paradigm above. Fiber photometry recordings
were made throughout the entirety of 2-hour progressive ratio operant conditioning sessions. Prior
to recording during operant behavior sessions, an optic fiber was attached to the implanted fiber
using a ferrule sleeve (Doric, ZR_2.5). Two LEDs were used to excite GCaMP6s. A 531-Hz
sinusoidal LED light (Thorlabs, LED light: M470F3; LED driver: DC4104) was bandpass filtered
(470 ± 20 nm, Doric, FMC4) to excite GCaMP6s and evoke Ca2+-dependent emission. A 211-Hz
sinusoidal LED light (Thorlabs, LED light: M405FP1; LED driver: DC4104) was bandpass filtered
(405 ± 10 nm, Doric, FMC4) to excite GCaMP6s and evoke Ca2+-independent isosbestic control
emission. Laser intensity for the 470 nm and 405 nm wavelength bands were measured at the tip
of the optic fiber and adjusted to 50 uW before each day of recording. GCaMP6s fluorescence
traveled through the same optic fiber before being bandpass filtered (525 ± 25 nm, Doric, FMC4),
transduced by a femtowatt silicon photoreceiver (Newport, 2151) and recorded by a real-time
processor (TDT, RZ5P). The envelopes of the 531-Hz and 211-Hz signals were extracted in realtime by the TDT program Synapse at a sampling rate of 1017.25 Hz.
Quantification and Analysis:
All experiments were performed at least twice, including each treatment condition to
prevent an unspecific day/condition effect. Treatment groups were randomly assigned to animals
prior to testing. After assessing the normality of sample data using D'Agostino & Pearson test and
Shapiro-Wilk test, statistical significance was taken as *p < 0.05, **p < 0.01, ***p < 0.001, and
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****p < 0.0001, as determined by two - way repeated-measures ANOVA followed by two tailed
Sidak post hoc test, Friedman’s test, two tailed unpaired t test, two tailed paired t test, KruskalWallis, Dunn’s multiple comparisons test, two tailed Wilcoxon test, uncorrected Dunn’s test,
Dunnett’s multiple comparisons test, Kolmogorov-Smirnov test, one sample t test, two tailed
Mann-Whitney for unpaired values as appropriate. For correlation analysis between neuronal
counts and percent motivation change (Figure 4 i-k) Hartigan dip test was used to test for nonunimodality (permutation number = 20 000), followed by comparison of medians in nonparametric way using Wilcoxon Rank Sum test. Correlation within the bimodally distributed
groups, or all data combined was performed using Spearman test.
All data are expressed as mean ± SEM. Sample sizes (N number) always refers to value obtained
form an individual animal in all behavioral experiments (Figures 1, 2, 3, 6, 7, 8, 10, 11, 13, 14,
15, 16, 17), individual cell recordings (Figure 4, 5) or slice analysis (Figure 9, 12). Statistical
analysis was performed in GraphPad Prism 8.1.0 and MatLab.
Custom MatLab scripts were developed for analyzing fiber photometry data in context of
rat behavior. The isosbestic 405 nm excitation control signal was subtracted from the 470 nm
excitation signal to remove movement artifacts from intracellular Ca2+-dependent GCaMP6s
fluorescence. Baseline drift was evident in the signal due to slow photobleaching artifacts,
particularly during the first several minutes of each 2-hour recording session. A double exponential
curve was fit to the raw trace and subtracted to correct for baseline drift. After baseline correction,
the photometry trace was normalized to units of “∆F/F”, using the median fluorescence of the
entire session for subtraction and division. The post-processed fiber photometry signal was
analyzed in the context of progressive ratio task performance. For equivalent comparison between
baseline and post-CFA PR sessions, analysis of mean fluorescence relative to lever press times
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and reward attainment times was restricted to the minimum number of lever presses (first 34 lever
presses per session) and rewards (first 6 rewards per session) obtained by an animal within a given
session. “Transient event rate” for individual sessions was determined by identifying local maxima
in ∆F/F photometry signal that resemble the waveform and temporal dynamics of GCaMP6s
calcium transients. Built-in MatLab function “findpeaks” was used to identify local maxima that
were at least 1.2% ∆F/F in prominence and at least 150 ms in width at half prominence (Figure
2). MatLab codes available upon request.
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2.4 Results
Pain suppresses VTA DA neuron activity and alters the dynamics of DA cell firing during
motivated behavior.
To assess the impact of pain on the activity of VTA DA neurons during motivated behavior,
we employed a combination of calcium imaging using in vivo fiber photometry during sucrose
self-administration. A progressive ratio (PR) schedule of reinforcement for sucrose was used to
assess rats’ motivation.24 During this test, the number of lever presses necessary to obtain the
subsequent reward increases exponentially. Thus, the number of rewards obtained during the PR
session, referred to as break point, provides a direct measure of animal’s motivational state.24,25
In order to selectively record DA neuron calcium transients during this task we locally
injected a Cre-dependent calcium sensor (AAV-DJ-EF1a-DIO-GCaMP6s) and implanted an optic
fiber in the VTA of rats expressing Cre recombinase in TH positive (TH-Cre) neurons (Figure 1
a, b). Calcium transients from VTA infected cells were recorded during last day of each training
session on fixed ratio (FR) schedules FR1, FR2, FR5 (1,2 and 5 lever presses respectively result
in a reward delivery) and PR sessions (Figure 1 a). To assess the impact of pain on calcium
transients of VTA DA neurons animals received an intraplantar injection of either Complete
Freund’s Adjuvant (CFA) as a model of inflammatory pain, or saline as a control (Figure 1 a and
Figure 2 c, f).
The number of local maxima of DA calcium transients per minute throughout an entire PR
session was significantly decreased forty-eight hours after the CFA injection (Figure 1 c, i and
Figure 2 i). Interestingly, transient event rate in saline injected animals remained unchanged,
suggesting that repeating the PR session does not alter overall activity of VTA DA neurons (Figure
1 c, i and Figure 2 g).
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As previously reported, rats’ motivation for sucrose rewards was diminished forty-eight
hours after the CFA injection measured by a decrease in the number of pellets obtained during the
PR session (Figure 1 h and Figure 2 h, j). Furthermore, there were no significant differences in
DA activity during reward seeking behavior (VTA DA activity aligned to a correct lever press) in
either CFA or saline injected animals (Figure 2 a, b, d, e). However, phasic DA activity associated
with the reward delivery was significantly increased following administration of CFA relative to
baseline (pre-CFA) recordings (Figure 1 d-g, j). This finding suggests that the phasic VTA DA
neuron activity for the same reward value is enhanced in pain. Moreover, these results indicate
that pain diminishes overall frequency of VTA DA calcium transients during a motivational task,
leading to a decrease in motivation for natural rewards.
To assess persistence of pain effects on motivation and DA neuron activity we tested the
same parameters one week after the CFA injection. Interestingly, while CFA-induced hyperalgesia
persisted at one week post the injection, animals’ motivation for sucrose rewards was restored
(Figure 3 c, d, j). Consistent with this, overall VTA DA neuron calcium activity and phasic
responses aligned to reward delivery were restored to baseline levels as well (Figure 3 a, b, e-i).
This finding further supports the conclusion that an impairment in VTA DA neuron activity is
necessary to drive the effects of pain on motivated behavior.
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Figure 1. CFA decreases frequency of VTA DA neuron calcium transients but amplifies phasic response to
reward. a. Schematic representation of viral injection and behavioral methodology. b. Representative image of optic
fiber placement and GCaMP (green) expressing VTA DA neurons. c. Representative Ca2+ transients of the VTA DA
neurons during the entire baseline (grey) and post-SAL (blue) / post-CFA (red) PR sessions of sucrose selfadministration. d. Representative heat-maps of fluorescence aligned to the reward delivery (time point 0) for baseline
and post-SAL PR sessions for same animal. e. Mean fluorescence aligned to reward delivery for baseline (grey) and
post-SAL (blue) PR sessions (n = 5 rats). f. Representative heat-maps of fluorescence aligned to the reward delivery
(time point 0) for baseline and post-CFA PR sessions for same animal. g. Mean fluorescence aligned to reward delivery
for baseline (grey) and post-CFA (red) PR sessions (n = 7 rats). h. Pain decreases motivation for sucrose rewards
(two-way ANOVA for repeated measures, time: F1, 10 = 16.08, p=0.0025; interaction (time x treatment): F1, 10 = 4.143,
p=0.0692; Sidak’s post hoc between PR2 and PR21: CFA (n=7), ** p = 0.0017) i. Pain diminishes frequency of calcium
transients of VTA DA neurons (two-tailed Wilcoxon test, * p = 0.0156). j. Maximum fluorescence following reward
delivery (2-5 seconds after) is increased in the condition of pain (two-way ANOVA for repeated measures, time: F1,
10 = 8.520, p=0.0047; interaction (time x treatment): F1, 10 = 2.490, p=0.1191; Sidak’s post hoc between PR2 and PR1:
CFA (n=7), ** p = 0.0017). The data are presented as the mean ± s.e.m.
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Figure 2. VTA DA neuron aligned to reward seeking. Representative heat-maps of fluorescence aligned to the lever
press (time point 0) for baseline (grey) and post-SAL (blue) PR sessions for same animal. b. Mean fluorescence
aligned to lever press for baseline (grey) and post-SAL (blue) PR sessions (n = 5 rats) c. Saline injection does not alter
latency of paw withdrawal to noxious stimulus using Hargraves test. d. Representative heat-maps of fluorescence
aligned to the lever press (time point 0) for baseline (grey) and post-CFA (red) PR sessions for same animal. e. Mean
fluorescence aligned to lever press for baseline (grey) and post-CFA (red) PR sessions (n = 7 rats). f. Latency to
withdraw a paw from a noxious stimulus is decrease in CFA, resulting in hyperalgesia (two tailed Wilcoxon test, * p
= 0.0156, n = 7 rats). g. Transient events per minute of VTA DA neurons throughout the PR sessions are not altered
after the injection of saline. h. Saline doesn’t affect the numbers of correct lever presses during PR session. i. CFA
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decreases overall frequency VTA DA neurons calcium transients during PR session (two tailed Wilcoxon test, * p =
0.0156, n = 7 rats). j. CFA decreases the number of correct lever presses during PR session (two-tailed Wilcoxon test,
* p = 0.0156, n=7 rats). k. Cartoon depiction of minimal criteria of fluorescent maxima to be classified as calcium
transient event. l. Raw transduced fluorescent emission from excitation with 405 nm light (black trace) and 470 nm
light (blue trace). m. Double exponential curve fit (magenta) to the subtracted signal (470nm signal – 405nm signal).
n. Normalized and baseline-corrected fluorescence after the subtraction of double exponential curve.

Figure 3. VTA DA activity and motivation is recovered 1 week after the CFA injection. Representative Ca2+
transients of the VTA DA neurons during the entire baseline (grey) and 1 week post-CFA (green) PR sessions of
sucrose self-administration b. Transient events per minute of VTA DA neurons throughout the PR session is recovered
at 1 week post-CFA. c. Motivation for sucrose pellets is restored 1 week after the induction of pain. d. Number of
correct lever presses is not significantly altered at 1 week post-CFA. e. Representative heat-maps of fluorescence
aligned to the reward delivery (time point 0) for baseline and 1 week post-CFA PR sessions for same animal. f. Mean
fluorescence aligned to reward attainment for baseline (grey) and 1 week post-CFA (green) PR sessions (n = 5 rats).
g. Maximum fluorescence following reward delivery (2-5 seconds after) is not altered 1 week after the CFA injection.
h. Representative heat-maps of fluorescence aligned to the lever press (time point 0) for baseline and 1 week postCFA PR sessions for same animal. i. Mean fluorescence aligned to lever press for baseline (grey) and 1 week postCFA (green) PR sessions (n = 5 rats). j. Decrease latency to paw withdrawal persists 1 week post-CFA (two-tailed
paired t test, *** p = 0.0005, n = 5 rats).
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Pain decreases intrinsic excitability of VTA DA cells and increases inhibitory drive onto them.
To dissect the physiological mechanisms underlying the overall decrease in the frequency
of VTA DA calcium transients during pain as described above, we used ex vivo patch-clamp
recordings from CFA-injected and saline-injected rats (Figure 4 a). VTA DA neurons were
identified by a cellular capacitance > 30 pF, spontaneous firing below 5 Hz and the presence of a
hyperpolarization-activated cation current, Ih.26,27 (Figure 4 a). Here, we found that the resting
membrane potential (RMP) of DA neurons was decreased in CFA as compared to saline injected
controls, making VTA DA cells hyperpolarized in the CFA group (Figure 4 b and Figure 5 b).
We assessed the contribution of inhibitory inputs to this decrease in excitability, by washing
artificial cerebrospinal fluid (aCSF) containing the GABA A receptor antagonist picrotoxin (PTX)
onto the slice. Interestingly, while the application of PTX had negligible effect on the control saline
group, it depolarized the VTA DA cells from the CFA group to levels comparable to saline animals
(Figure 4 b and Figure 5 b). In addition, we found that the rheobase, calculated by injecting a
ramp of current to determine the minimum amount of current required to generate an action
potential, was significantly higher in CFA injected animals (Figure 4 c and Figure 5 c). This
effect was also abolished upon the application of PTX indicating that less current is required to
depolarize cells to fire an action potential after PTX application (Figure 4 c and Figure 5 c).
Furthermore, while input resistance was not affected by CFA, we found that application of PTX
increases input resistance only in CFA treated animals (Figure 4 d and Figure 5 d). However,
action potential threshold remained unchanged regardless of the presence of CFA or PTX (Figure
5 a).
We further characterized the intrinsic excitability of VTA DA neurons by examining the
input-output curves from CFA and saline injected animals. Input-output curves were generated
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with 200 ms current steps injected in increments of 10 pA from 0 to 200 pA. We found that the
input-output curve was not impacted by CFA or the application of PTX, as no groups demonstrated
significant difference at any current steps (Figure 4 g, h). Moreover, the firing rate of VTA DA
neurons was lower, although not significant, in CFA group (Figure 4 e, f). Taken together, our
results demonstrate that while lower intrinsic excitability of VTA DA neuron in pain is mediated
through increased GABAergic drive the lack of effect of PTX on the spontaneous activity of DA
cells in pain suggests that additional, GABA-independent, cell-autonomous adaptations also
contribute to this decrease in spontaneous activity in slices.
To directly test the hypothesis that inhibitory drive is increased onto VTA DA neurons
following pain induction, we next measured the spontaneous inhibitory postsynaptic currents
(sIPSC) as a reflection of spontaneous neurotransmitter release. We found that the distribution of
interevent interval (IEI) of sIPSCs, but not the amplitude was significantly decreased in CFA
treated rats (Figure 4 i-k). This CFA-induced increase in the frequency of spontaneous events
indicates enhanced pre-synaptic release, further supporting the conclusion that inhibitory drive
onto VTA DA neurons is increased in pain (Figure 4 j).
Taken together, these findings reveal that VTA DA neurons are less excitable following
CFA-treatment, and that increased inhibitory GABAergic drive contributes to this effect.
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Figure 4. VTA DA cells are hyperpolarized in CFA injected animals, exhibiting decreased intrinsic excitability
and increased inhibitory drive onto them. a. Representative picture of a patch pipette onto the soma of a VTA DA
neuron. Identification of DA neurons by the presence of large hyperpolarization-activated inward current, Ih. b.
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Resting membrane potential (RMP) is lower in CFA group. Application of PTX restores RMP to the level of saline
injected animals (two-way ANOVA for repeated measures, treatment (PTX): F1, 42 = 13.36, p=0.0007; interaction
(treatment (PTX) x treatment (CFA/SAL)) : F1, 42 = 10.50, p=0.0023; Sidak’s post hoc between CFA and SAL: ** p =
0.0046 at baseline, Sidak’s post hoc between PTX and baseline: CFA,**** p < 0.0001, n (SAL) = 21 cells from 5 rats,
n (CFA) = 23 cells from 4 rats). c. Amount of current necessary to evoke first action potential is higher in CFA treated
rats. This effect is eliminated upon application of PTX (two-way ANOVA for repeated measures, treatment (PTX):
F1, 40 = 1.327, p=0.2562; interaction (treatment (PTX) x treatment (CFA/SAL)): F1, 40 = 6.113, p=0.0178; Sidak’s post
hoc between CFA and SAL: ** p = 0.0021 at baseline, Sidak’s post hoc between PTX and baseline: CFA, * p =
0.0242, n (SAL) = 20 cells from 5 rats, n (CFA) = 23 cells from 4 rats). d. CFA does not alter input resistance, while
application of PTX increases input resistance in the CFA treated animals (two-way ANOVA for repeated measures,
treatment (PTX): F1, 42 = 3.037, p=0.0887; interaction (treatment (PTX) x treatment (CFA/SAL)): F 1, 42 = 3.520,
p=0.0676; Sidak’s post hoc between PTX and baseline: CFA, * p = 0.0243, n (SAL) = 21 cells from 5 rats, n (CFA)
= 23 cells from 4 rats. e. Representative traces of spontaneous activity. f. Spontaneous firing rate of VTA DA neurons
is lower in the condition of pain. (two-way ANOVA for repeated measures, treatment (PTX): F1, 42 = 1.432, p=0.2382;
interaction (treatment (PTX) x treatment (CFA/SAL)): F1, 42 = 0.4356, p=0.5129; Sidak’s post hoc between CFA and
SAL upon application of PTX: * p = 0.0126, n (SAL) = 21 cells from 5 rats, n (CFA) = 23 cells from 4 rats). g.
Representative input-output traces. h. The input-output curve of neuronal excitability is not altered by pain or PTX. i.
Representative traces of spontaneous IPSCs. j. Frequency of sIPSCs is increased in condition of pain which as in
indicative of increased inhibitory drive onto VTA DA neurons (distribution of cumulative probability for IEI:
Kolmorogov-Smirnov test = 4.925, *** p< 0.05; mean IEI: **** p < 0.0001, two-tailed Mann Whitney test, n (SAL)
= 27 from 5 rats, n (CFA) = 25 from 5 rats). k. Mean amplitude of sIPSCs is not altered by pain. The data are presented
as the mean ± s.e.m.

Figure 5. Intrinsic excitability of VTA DA neurons is decreased in CFA injected animals. Related to Figure 2.
a. Action potential threshold is not altered in either by CFA or upon application of PTX (n (SAL) = 21 cells from 5
rats, n (CFA) = 23 cells from 4 rats). b. Application of picrotoxin (PTX) further depolarized cells from the CFA group
while it has no effect on the cells from saline injected animals (one sample t test compared to 100 percent, CFA, ****
p < 0.0001, n (SAL) = 21 cells from 5 rats, n (CFA) = 23 cells from 4 rats). c. Application of picrotoxin (PTX)
decreases the amount of current required to depolarize cells to fire an action potential in CFA treated animals (one
sample t test compared to 100 percent, CFA, ** p = 0.0031, n (SAL) = 20 cells from 5 rats, n (CFA) = 22 cells from
4 rats). d. PTX increased input resistance in CFA but not saline treated animals (one sample t test compared to 100
percent, CFA, * p = 0.0373, n (SAL) = 21 cells from 5 rats, n (CFA) = 23 cells from 4 rats).
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Chemogenetic activation of VTA DA neurons, or VTA-NAc pathway, is sufficient to prevent paininduced decrease in motivation.
Our photometry data indicates that pain-induced impairment in VTA DA cell activity
occurs in parallel with a decrease in motivation for sucrose rewards. Thus, we hypothesized that
in vivo activation of VTA DA neurons would be sufficient to prevent pain-induced deficits in
motivated behavior. To investigate this, we utilized a combination of chemogenetics with a PR
schedule of reinforcement for sucrose self-administration. In order to selectively activate VTA DA
neurons we bilaterally injected Cre-dependent excitatory Designer Receptors Exclusively
Activated by Designer Drugs (DREADDs) (AAV5-hSyn-DIO-hM3D(Gq)-mCherry) or control
virus (AAV5-Ef1a-DIO-mCherry) in the VTA of TH-Cre rats (Figure 6 a,b, Figure 8 a and
Figure 9 a). We found that activation of DREADD-expressing DA neurons, via subcutaneous
(s.c.) injection of CNO (1mg.kg-1) during second PR session, was sufficient to prevent CFAinduced decrease in motivation for the self-administration of sucrose pellets (Figure 6 c).
Importantly, CFA control groups injected with DREADD virus or CNO alone, demonstrated a
decrease in motivation for sucrose pellets on the second PR test, confirming that the observed
restoration in motivated behavior is tightly associated with VTA DA neuron activation (Figure 6
c and Figure 7 a). Moreover, this effect was not mediated through an overall change in locomotor
activity which was only observed upon activation of DREADDs in saline, but not CFA treated
animals (Figure 11 a, c).
In addition, we assessed whether CNO application led to an increase in DREADD
expressing DA neurons activation using cFos expression as a proxy for neuronal activation.28 First,
we demonstrated that both control and DREADD viral expression were highly restricted to TH
positive (DA) neurons in the VTA (Figure 10 a, b). Moreover, we observed that around 70% of
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TH positive neurons expressing DREADDs were co-labeled with cFos, while control groups
showed a significantly lower co-labeling and overall expression of cFos (Figure 10 c). This result
further substantiates the high selectivity for DREADD expressing neuronal activation upon CNO
administration.
The VTA to NAc mesolimbic pathway is a key circuit encoding motivational processes12,15,
with NAc shell (NAcSh) mediating both aversive stimuli such as pain as well as motivational
salience.21,29–31 Thus we next investigated whether activation of VTA neurons projecting to NAcSh
would be sufficient to reverse the pain-induced decrease in motivation for sucrose.32 Wild type
rats were injected with a retrograde canine adenovirus carrying Cre recombinase (CAV2-Cre)33 in
the NAcSh and a Cre-dependent excitatory DREADDs (AAV5-hSyn-DIO-hM3D(Gq)-mCherry),
or a control virus (AAV5-Ef1a-DIO-mCherry) in the VTA (Figure 6 e,f Figure 8 b and Figure
9 b). Interestingly, chemogenetic activation of VTA to NAcSh projection neurons was sufficient
to prevent CFA-induced decrease in rewards obtained during in the PR task (Figure 6 g and
Figure 7 b). Furthermore, we observed a significant bimodal distribution of the animal
performance during the second PR session in CFA group, with a cluster of animals whose
motivation was substantially decrease and a cluster of animals with minimal change in motivation
(Figure 6 i-k and Figure 8 c). Importantly, the percent of motivation change was correlated with
the infection rate of the virus, while no significant correlation was found within cluster population
(Figure 6 i-k).
Since previous work has demonstrated that pain relief enhances DA transmission in the
VTA to NAcSh pathway34,35, we next assessed whether our chemogenetic approaches would
produce analgesia and thus restore motivation for sucrose seeking. To test this hypothesis, we
measured thermal hyperalgesia using the Hargreaves test. Neither general enhancement of the
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VTA DA neurons, or selective activation of VTA-NAcSh pathway was able to reverse CFAinduced hyperalgesia (Figure 6 d,h). Together, these results indicate that selective activation of
mesolimbic VTA-NAc pathway or VTA DA neurons is sufficient to prevent the observed paininduced decrease in motivated behavior without impacting the sensory component of pain.
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Figure 6. Chemogenetic activation of VTA DA neurons, or VTA-NAc pathway, prevents CFA induced decrease
in motivation. a. Schematic representation of viral injection and behavioral methodology. b. Representative coronal
section of VTA Gq DREADD expressing neurons. Blue – DAPI; Red – m-Cherry (Gq DREADD); Green – TH (DA
neurons). c. Activation of DA containing neurons in the VTA prevents CFA induced decrease in motivation for sucrose
pellets. Animals injected with control virus and CNO alone showed decrease in motivation after the CFA injection
(two-way ANOVA for repeated measures, time: F1, 47 = 46.35, p<0.0001; interaction (time x treatment): F3, 47 = 45.18,
p<0.0001; Sidak’s post hoc between groups during PR2: hM3Dq + CFA + VEH (n=10) versus hM3Dq + SAL+ CNO
(n=14) , $$$$ p<0.001, hM3Dq + CFA + VEH versus hM3Dq + CFA+ CNO (n=17), #### p<0.001; m-Cherry + CFA +
CNO (n=10) versus hM3Dq + SAL+ CNO, $$$$ p<0.001, m-Cherry + CFA + CNO versus hM3Dq + CFA+ CNO, ####
p<0.001). d. CFA induced hyperalgesia is not altered by activation of DA containing neurons in the VTA (two-way
ANOVA for repeated measures, time: F2, 94 = 507.2, p<0.0001; interaction (time x treatment): F6, 94 = 59.72, p<0.0001;
Sidak’s post hoc for each group as compared to the group’s baseline session: **** p<0.0001). e. Schematic
representation of viral injection and behavioral methodology. f. Representative coronal section of VTA Gq DREADD
expressing neurons. Blue – DAPI; Red – m-Cherry (Gq DREADD); Green – TH (DA neurons). g. Activation of
NAcSh projecting VTA neurons prevents CFA induced decrease in motivated behavior. Control CFA animals injected
with either CNO or virus alone show decrease in motivation (two-way ANOVA for repeated measures, time: F1, 53 =
148.4, p<0.0001; interaction (time x treatment): F3, 53 = 14.66, p<0.0001; Sidak’s post hoc during PR2 between the
groups: hM3Dq + CFA + VEH (n=17) versus hM3Dq + SAL+ CNO (n=12), $$$ p=0.0004, hM3Dq + CFA + VEH versus
hM3Dq + CFA + CNO (n=17), ## p=0.0085; m-Cherry + CFA + CNO (n=11) versus hM3Dq + SAL+ CNO, $$ p=0.0024,
m-Cherry + CFA + CNO versus hM3Dq + CFA + CNO, # p=0.0344). h. CFA-induced hyperalgesia is not altered by
activation of VTA-NAc pathway. (two-way ANOVA for repeated measures, time: F2, 106 = 597.4, p<0.0001;
interaction (time x treatment): F6, 106 = 74.90, p<0.0001; Sidak’s post hoc for each group as compared to the group’s
baseline session: **** p<0.0001). i-k. Bimodal distribution of the animal’s performance during second PR session is
observed in hM3Dq + CFA + CNO test group (p=0.0312, Hartigan dip test, number of shuffles 20 000). The percent
of motivation change is corelated with the infection rate of the virus. (total number of VTA-NAc m-Cherry expressing
neurons r=0.6292, p=0.0068, n=17 rats, Spearman correlation test; the number VTA-NAc m-Cherry expressing
neurons positive for TH r=0.7446, p=0.0006, n=17 rats, Spearman correlation test; number of m-Cherry expressing
TH negative neurons r=0.539, p=0.0256, n=17 rats, Spearman correlation test). The data are presented as the
mean ± s.e.m.

64

Figure 7. Chemogenetic activation of VTA DA neurons, or VTA-NAcSh pathway prevents CFA induced
decrease in number of correct lever presses for sucrose rewards in PR task. Activation of DA containing neurons
in the VTA prevents CFA induced decrease in number of correct lever presses in sucrose PR. Animals injected with
control virus and CNO alone showed decrease in the number of correct lever presses after the CFA injection (twoway ANOVA for repeated measures, time: F1, 47 = 3.361, p=0.0731; interaction (time x treatment): F3, 47 = 21.02,
p<0.0001; Sidak’s post hoc between groups during PR2: hM3Dq + CFA + VEH (n=10) versus hM3Dq + SAL+ CNO
(n=14) , $$$$ p<0.001, hM3Dq + CFA + VEH versus hM3Dq + CFA+ CNO (n=17), ## p<0.0020; m-Cherry + CFA +
CNO (n=10) versus hM3Dq + SAL+ CNO, $$$$ p<0.0001, m-Cherry + CFA + CNO versus hM3Dq + CFA+ CNO, ##
p=0.0028), hM3Dq + CFA+ CNO versus hM3Dq + SAL+ CNO, $ p=0.0188). b. Activation of NAcSh projecting
VTA neurons prevents CFA induced decrease in number of correct lever presses in sucrose PR. Control CFA animals
injected with either CNO or virus alone show decrease in number of correct lever presses in sucrose PR (two-way
ANOVA for repeated measures, time: F1, 53 = 87.59, p<0.0001; interaction (time x treatment): F3, 53 = 4.036, p=0.0117;
Sidak’s post hoc during PR2 between the groups: hM3Dq + CFA + VEH (n=17) versus hM3Dq + SAL+ CNO (n=12), $$
p=0.0021, m-Cherry + CFA + CNO (n=11) versus hM3Dq + SAL+ CNO, $ p=0.0116).

Figure 8. Viral expression and histological
verification. a. Representative coronal section of
VTA DREADD expressing neurons. Blue – DAPI;
Red – m-Cherry (Gq DREADD); Green – TH (DA
neurons). Schematic representation of viral injections
for Gq DREADD injected TH cre+ rats used for
chemogenetic experiments in Figure 3 a-d. b.
Representative coronal section of VTA Gq
DREADD expressing neurons. Blue – DAPI; Red –
m-Cherry (Gq DREADD); Green – TH (DA
neurons). Schematic representation of viral injections
for Gq DREADD injected wild type rats used in
chemogenetics experiment in Figure 3 e-k. c.
Representative images of low viral infection rate (red
dotted line) correlated with decrease in motivation
(red circle) and high viral infection rate (blue dotted
line) correlated with no change in motivation (blue
circle) during PR test using intersectional
chemogenetics in CFA treated animals.
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Figure 9. Spread of viral expression in the VTA. a. Spread of overlay of individual animal viral expression across
VTA in DREADD and control m-Cherry injected TH-cre animals used in Figure 3 b-d. b. Spread of overlay of
individual animal viral expression across VTA in DREADD and control m-Cherry injected WT animals used in Figure
3 f-k.
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Figure 10. Validation of chemogenetic activation of VTA DA neurons. a. Representative coronal section of VTA
DA neurons expressing DREADDs and cFos. Blue – cFos; Red – m-Cherry (Gq DREADD); Green – TH (DA
neurons). b. Expression of mCherry is highly specific to TH positive neurons. In addition, similar levels of expression
are seen between control and DREADD virus in the VTA. c. cFos expression is significantly increased only in
DREADD animals injected with CNO where it is highly selective for TH positive mCherry expressing neurons
(ANOVA Kruskal-Wallis multiple comparisons *** p = 0.0002; uncorrected Dunn’s post-hoc between groups;
hM3Dq + SAL (n=5) versus hM3Dq CNO (n=5), ** p = 0.0011; m-Cherry + CNO (n=5) versus hM3Dq + CNO, * p =
0.0401)
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Figure 11. Increase in locomotor activity is only observed upon activation of DREADDs in saline injected but
not CFA injected animals. a. Chemogenetic activation increases distance traveled in saline injected animals. Animals
in CFA group do not show alteration in locomotor activity upon activation of VTA DA neurons (open bars -baseline,
filled bars – 48 hours post CFA/SAL two-way ANOVA for repeated measures, time: F1, 31 = 0.4334, p=0.5152;
interaction (time x treatment): F3, 31 = 3.742, p=0.021; Sidak’s post hoc between baseline session and 48 hours post
CFA/SAL (within group): hM3Dq + SAL+ CNO (n=8), * p = 0.0161). b. CFA induced hyperalgesia persists after
chemogenetic activation of VTA DA neurons (two-way ANOVA for repeated measures, time: F2, 64 = 71.01, p<0.0001;
interaction: F6, 64 = 7.672, p<0.0001; Sidak’s post hoc for each group as compared to the group’s baseline session:
**** p<0.0001). c. Spread of overlay of individual animal viral expression across VTA in DREADD and control mCherry injected TH-cre animals.
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Chemogenetic activation of VTA-NAc DA terminals prevents pain induced decrease in motivation.
Recent studies point to an important role of local intra-striatal regulation of DA
release.21,25–27,29 While we show that enhanced activation of VTA-NAc pathway is sufficient to
prevent pain induced decrease in motivation, the specific contribution of DA neurons within this
pathway is yet to be determined. Thus, we examined the effects of pain on the properties of DA
release in NAcSh using fast-scanning cyclic voltammetry (FSCV) to record ex vivo evoked DA
transients from mouse brain slices forty-eight hours after CFA or saline injection. DA transients
were evoked using both electrical and optogenetic approach.
We found a small decrease in the amplitude of the evoked transients in the CFA-injected
mice at submaximal stimulations (Figure 12 c), indicative of a small impairment in the ability to
electrically evoke DA release at the synaptic terminal following the induction of pain. However,
other properties of DA release remain largely unaffected by pain.
One of the limitations of this approach is that recordings were made in an ex vivo slice
preparation where many of the connections were not intact. To circumvent this limitation, we
instead utilized in vivo chemogenetic approach in combination with progressive ratio for sucrose
self-administration. To this end we bilaterally injected Cre-dependent excitatory DREADDs
(AAV5-hSyn-DIO-hM3D(Gq)-mCherry) or control virus (AAV5-Ef1a-DIO-mCherry) in the
VTA of TH-Cre rats and implanted intra – NAcSh cannula for the local delivery of 1mM of CNO
or aCSF (Figure 13 a, b and Figure 14 b,c). Chemogenetic enhancement of NAcSh projecting
VTA DA terminals prevented CFA-induced decrease in motivation for sucrose rewards without
altering CFA-induced hyperalgesia (Figure 13 c, d and Figure 14 a). This finding further
strengthens the hypothesis that restoring DA neurotransmission selectively within the NAcSh is
necessary to restore motivation for sucrose following CFA treatment.
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Figure 12. Pain does not alter ex vivo properties of dopamine release at the axon terminals in nucleus
accumbens. DA transients were measured using fast-scanning cyclic voltammetery in ex vivo brain slices containing
the nucleus accumbens shell (NAcSh) and were evoked by electrical stimulation (a-e) or optogenetic stimulation of
dopamine neuron fibers (f-j). a. Left: picture of sagittal section of mouse brain. The recording was made NacSh,
denoted with a rectangle. Right: IR picture of the brain slice with a carbon fiber electrode (right) and a stimulation
electrode (left) for electrical stimulation in the NAcSh b. Representative traces of DA transients are shown for saline
(black) and CFA (red) treated mice with their corresponding current-voltage plots (inset). Transients were evoked
electrically. c. Peak amplitudes of DA transients as a function of stimulation intensity for electrically evoked signals.
d. Normalized amplitude of DA transients evoked by a train of 4 pulses of electrical stimulation delivered at varying
frequencies in ACSF. Amplitude were normalized to peak amplitude of single pulse evoked transients e. Decay time
constants of DA transients relate to the DA re-uptake mechanisms for electrically evoked signals. f. Left : fluorescence
image, showing the cre-dependent expression of ChR2-YFP in VTA and in the NAc, where DA neurons project.
Right: IR image of sagittal section with a carbon fiber electrode (right) and a fiber optics (bottom) for optogenetic
stimulation in the NAcSh g. Representative traces of DA transients are shown for saline (black) and CFA (red) treated
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mice with their corresponding current-voltage plots (inset). Transients were evoked optogenetically. h. Peak
amplitudes of DA transients as a function of stimulation intensity for light-evoked signals. i. Normalized amplitude
of light-evoked DA transients as a function of the frequency of a train of 4 pulses. Amplitudes were normalized to
peak amplitude of transients evoked by single pulse stimulation. j. Decay time constants of DA transients relate to the
DA re-uptake mechanisms for light-evoked signals.

Figure 13. Chemogenetic activation of NAcSh projecting VTA DA neurons mitigates the effect of CFA on
motivated behavior. a. Schematic representation of viral injection and behavioral methodology. b. Representative
coronal section of NAcSh cannula placement and terminal expression of DREADDs injected in the VTA of TH-cre
rats. Blue – DAPI; Red – m-Cherry (Gq DREADD); Green – TH (DA neuron terminals). c. Chemogenetic
enhancement of VTA-NAcSh projecting DA neurons prevents CFA induced decrease in motivation (two-way
ANOVA for repeated measures, time: F1, 27 = 53.97, p<0.0001; interaction (time x treatment): F3, 27 =17.31, p<0.0001;
Sidak’s post hoc during PR2 between the groups: hM3Dq + CFA + VEH (n=7) versus hM3Dq + SAL+ CNO (n=8) , $$$$
p<0.0001, hM3Dq + CFA + VEH versus hM3Dq + CFA+ CNO (n=8), ## p = 0.0012; m-Cherry + CFA + CNO (n=8)
versus hM3Dq + SAL+ CNO, $$$$ p<0.0001, m-Cherry + CFA + CNO versus hM3Dq + CFA+ CNO, ####
p<0.0001). d. Chemogenetic enhancement of VTA-NAcSh projecting DA neurons does not alter CFA induced
hyperalgesia (two-way ANOVA for repeated measures, time: F2, 54 = 233.9, p<0.0001; interaction (time x treatment):
F6, 54 = 26.38, p<0.0001; Sidak’s post hoc for each group as compared to the group’s baseline session: **** p<0.000).
The data are presented as the mean ± s.e.m.
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Figure 14. Chemogenetic activation of NAcSH projecting VTA DA neurons, prevents CFA induced decrease in
number of correct lever presses for sucrose rewards in PR task. a. Activation of DA containing NAcSh projecting
VTA neurons prevents CFA induced decrease in number of correct lever presses in sucrose PR. Animals injected with
control virus and CNO alone showed decrease in the number of correct lever presses after the CFA injection (twoway ANOVA for repeated measures, time: F1, 27 = 8.016, p=0.0087; interaction (time x treatment): F3, 27 = 4.966,
p=0.0071; Sidak’s post hoc between groups during PR2: hM3Dq + CFA + VEH (n=7) versus hM3Dq + SAL+ CNO
(n=8) , $$$ p=0.0005; m-Cherry + CFA + CNO (n=8) versus hM3Dq + SAL+ CNO, $$$$ p<0.0001, m-Cherry + CFA +
CNO versus hM3Dq + CFA+ CNO(n=8), # p=0.0190). b. Schematic representation of cannula placement in the NAcSh
for local delivery of aCSF or CNO. c. Spread of overlay of individual animal viral expression across VTA in DREADD
and control m-Cherry injected TH-cre animals.
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Increasing the hedonic value of natural reward overcomes the effects of pain on sucrose
consumption.
We previously demonstrated that pain induces a rightward shift in the opioid dose response,
suggesting an impairment in rewarding properties of opioid drugs.19 Therefore, we sought to
examine whether pain also alters rewarding properties for natural rewards. Utilizing a PR of
sucrose self-administration in the above-mentioned experiments, we were able to measure the
motivation for consumption of a sucrose pellet. However, with this method we are not able to alter
the hedonic value of the reward (concentration of sucrose within the pellet itself). In order to assess
alterations in rewarding properties of sucrose rewards, we employed a two-bottle choice paradigm
during which an animal can freely choose between water or a sucrose solution for one hour.36 This
paradigm specifically allowed us to investigate the effect of pain on reward consumption during
escalating concentrations (values) of sucrose. To assure that sucrose concentrations used in the
two-bottle choice were not perceived as aversive, we measured orofacial reactivity such as
consummatory protrusions and hedonic licks for 5%, 30% and 60% sucrose in naïve animals
(Figure 16). We found that 5% and 30% sucrose significantly increased consummatory
protrusions as compared to water. We also observed an increase in consummatory protrusions
with 60% sucrose, although this was not significant (Figure 16 a). In addition, 60% sucrose
elicited exaggerated swallowing, possibly due to the increased viscosity of the solution. This
behavior is easily distinguishable from aversive gapes induced by quinine as presented in the
supplementary videos (Video 1, 2, 3). This data demonstrates that concentrations used in twobottle choice experiments are not aversive and produce similar orofacial responses.
During the two-bottle choice procedure animals underwent four days of habituation during
which they were simultaneously exposed to a 5% sucrose solution and a water bottle (Figure 15
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a). Following habituation sessions, a baseline test was performed and both sucrose (5%, 30% or
60%) and water volume consumed were recorded. Subsequently, CFA or saline was injected into
rat’s hindpaw and a second two-bottle choice test was performed 48 hours after pain induction
(Figure 15 a). We found that animals in CFA group decreased their voluntary consumption of 5%
and 30% sucrose solution compared to control saline injected animals (Figure 15 b, c, e).
Interestingly, the amount of water consumed was unchanged between the experimental groups,
suggesting that the observed changes in drinking behavior are specific to the sucrose consumption
and reflect an impairment in perceived hedonic value of sucrose reward in pain (Figure 16 b, c,
d). Furthermore, there was no significant difference in sucrose consumption between CFA and
saline injected animals when the concentration was increased to 60% (Figure 15 d, e). These data
indicate that pain alters rewarding properties only for lower reward values, while it does not impact
reward consumption when the sucrose value is increased, indicating a rightward shift in the
hedonic value of sucrose.
Lastly, using a chemogenetic approach we found that selective activation of VTA DA
neurons is sufficient to prevent CFA induced decrease in motivated behavior (Figure 6). Thus, we
assessed whether selective activation of VTA DA neurons could also prevent the CFA induced
decrease in 5% sucrose solution consumption. To test this, we bilaterally injected Cre-dependent
excitatory DREADDs (AAV5-hSyn-DIO-hM3D(Gq)-mCherry) or control virus (AAV5-Ef1aDIO-mCherry) in the VTA of TH-Cre rats (Figure 15 f and Figure 17 d, e). We show that
selective activation of VTA DA neurons prevented decrease in 5% sucrose solution consumption
in CFA treated animals (Figure 15 g and Figure 17 a-c). Importantly, in these conditions a
decrease in the amount of sucrose consumed was still observed in our CFA control groups injected
with either DREADD virus or CNO alone (Figure 15 g). These results indicate that the activation
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of VTA DA system is sufficient to prevent the decreased voluntary consumption of 5% sucrose
induced by pain, restoring normal hedonic responses to natural rewards.

Figure 15. Increasing the concentration of sucrose reward overcomes the effects of CFA on sucrose
consumption. a. Schematic representation of behavioral methodology. b-d. CFA induces significant decrease in the
amount of 5% and 30% sucrose consumed (open bars -baseline, filled bars – 48 hours post CFA/SAL. 5% sucrose
two-way ANOVA for repeated measures, time: F1, 23 = 6.387, p=0.0188; interaction (time x treatment): F1, 23 = 21.31,
p=0.0001; Sidak’s post hoc within group: CFA (n=13) baseline versus 48 hours post CFA, **** p<0.0001; 30% sucrose
two-way ANOVA for repeated measures, time: F1, 23=14.86, p=0.0008; interaction (time x treatment): F1, 23=4.105,
p=0.0545; Sidak’s post hoc within group: CFA (n=12) baseline versus 48 hours post CFA, *** p=0.0009). Increasing
the concentration of sucrose solution to 60% prevents pain-induced decrease in sucrose consumption. e. Sucrose
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consumption presented as percent change of baseline (5% sucrose two-tailed unpaired t test between CFA and VEH,
*** p=0. 0002: 30% sucrose two-tailed unpaired t test between CFA and VEH, * p=0.0409). f. Schematic of viral
injection and representative coronal section of VTA Gq DREADD expressing neurons. Blue – DAPI; Red – m-Cherry
(Gq DREADD); Green – TH (DA neurons). g. Chemogenetic activation of DA containing neurons in the VTA
prevents CFA induced decrease in consumption of 5% sucrose (Kruskal-Wallis test, ***P=0.0005; Dunn’s multiple
comparisons between groups: hM3Dq CFA + VEH (n=7) versus hM3Dq SAL + CNO (n=7), $ p=0.0183, hM3Dq CFA
+ VEH versus hM3Dq CFA + CNO (n=7), # p=0.0204; m-cherry CFA + CNO (n=6) versus hM3Dq SAL + CNO, $
p=0.0139, m-cherry CFA + CNO versus hM3Dq CFA + CNO, # p=0.0155). The data are presented as the
mean ± s.e.m.
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Figure 16. CFA does not alter intake of water during the sucrose two-bottle choice experiment. a. 5% and 30%
sucrose significantly increased consummatory protrusions as compared to water, with similar trend being seeing with
60% sucrose as well (ANOVA Friedman’s test, **** p < 0.0001; Dunn’s multiple comparisons post hoc: 5% sucrose
versus water, ** p = 0.0036; 30% sucrose versus water, * p = 0.0423, n = 5 rats). No changes are observed in number
of ingestive licks or the length of the lick between different concentrations. b. Volume of water consumed is not
changed after the CFA injection during either 5%, 30% or 60% sucrose two-bottle choice. c. CFA decreases 5%
sucrose preference during two-bottle choice (open bars -baseline, filled bars – 48 hours post CFA/SAL. two-way
ANOVA for repeated measures, time: F1, 23 = 2.339, p=0.1398; interaction (time x treatment): F1, 23 =4.446, p=0.0461;
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Sidak’s post hoc within group: CFA (n=13) baseline versus 48 hours post CFA, * p=0.03), while it has no effect on 30%
or 60% sucrose preference. d. CFA decreases latency to withdrawal from a noxious stimulus resulting in hyperalgesia
(two-way ANOVA for repeated measures, 5% sucrose time: F1,23= 91.75, p<0.0001; interaction (time x treatment):
F1,23 = 63.86, p<0.0001; Sidak’s post hoc for each group as compared to the group’s baseline session: **** p<0.0001;
30% sucrose time: F1,23= 40.71, p<0.0001; interaction (time x treatment): F1,23 = 20.02, p=0.0002; Sidak’s post hoc
for each group as compared to the group’s baseline session: **** p<0.0001; 60% sucrose time: F1,25= 72.34,
p<0.0001; interaction: F1,25 = 43.85, p<0.0001; Sidak’s post hoc for each group as compared to the group’s baseline
session: **** p<0.0001).
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Figure 17. Chemogenetic stimulation of VTA DA neurons does not alter water intake in two-bottle choice test.
a. Chemogenetic activation of DA containing neurons in the VTA does not alter sucrose preference in two-bottle
choice test. b. CFA induced hyperalgesia is not altered by activation of VTA DA neurons (two-way ANOVA for
repeated measures, time: F2, 48 = 148.2, p<0.0001; interaction (time x treatment): F6, 48 = 19.30, p<0.0001; Sidak’s post
hoc for each group as compared to the group’s baseline session: **** p<0.0001). c. Chemogenetic activation of DA
containing neurons in the VTA does not alter water consumption in two-bottle choice test. d. Representative coronal
section of VTA DREADD expressing neurons. Blue – DAPI; Red – m-Cherry (Gq DREADD); Green – TH (DA
neurons). e. Spread of overlay of individual animal viral expression across VTA in DREADD and control m-Cherry
injected TH-cre animals.
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2.5 Discussion
Pain triggers maladaptive changes within the mesolimbic reward pathway leading to the
development of negative affective states.21,22 We previously showed that within the mesolimbic
pathway, pain impairs mu opioid receptor (MOR)-mediated inhibition of GABA release in the
VTA.19 In the same line of evidence, inflammatory and neuropathic pain strongly alter opioidevoked DA release in the NAc.19,20 Similarly, alterations in the subpopulations of VTA DA neuron
firing properties in a neuropathic pain model have also been reported.37 However, direct evidence
for the impact of pain on VTA DA cell activity and excitability, and its role in mediating changes
seen in motivated behavior is lacking.
Here we report that the resting membrane potential of VTA DA neurons is significantly
decreased by pain. Furthermore, pain increases VTA DA neuron rheobase revealing that DA
neurons are less responsive during pain. These effects are abolished upon application of GABAA
receptor antagonist PTX to the slice demonstrating that the decrease in intrinsic excitability of
VTA DA cells is at least in part mediated via GABAergic inputs. Our data showing that the
frequency of sIPSCs is increased in the presence of pain further supports the conclusion that the
blunted activity of VTA DA neurons is mediated through GABAergic inputs as increased
frequency of sIPSCs is indicative of higher inhibitory drive onto VTA DA neurons. Taken together
with our previous studies, these findings suggest that pain downregulates the MOR system at
GABA terminals in the VTA, leading to increased inhibitory drive which results in decreased
excitability of VTA DA neurons.19,38 While not significant, an trend towards decrease in
spontaneous firing rate and input resistance in pain animals is also observed. This could be
explained by an increase variability in the data sets, suggestive of potentially divergent effects of
pain on subpopulations of VTA DA neurons as previously reported in a different pain model.37
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Additionally, altered excitatory glutamatergic inputs from ventrolateral periaqueductal gray
(vlPAG) could also play a role in making VTA DA neurons less active in conditions of pain.39 It
is also likely that pain not only dysregulates the DA system but rather multiple neurotransmitter
systems within the mesolimbic reward pathway to drive negative affective states.21,40
In this study, we found that pain-induced impairments in DA neuron firing correlate with
overall decreased frequency of VTA DA calcium transients during sucrose self-administration.
Interestingly, animals experiencing inflammatory pain have no significant changes in VTA DA
cell activity during lever presses while seeking for the reward, whereas their phasic DA activity
correlated with reward delivery is higher in pain conditions. One explanation could be that pain
impairs hedonic state of the animal by lowering the expected values of sucrose rewards and
mimicking positive reward prediction error (increased phasic responses to same sucrose rewards
in pain). Additionally, the change in phasic response could be due to the lower activity and higher
inhibition of VTA DA neurons at baseline. However, further studies utilizing decision-making
tasks and reinforcement learning are necessary to more closely assess this phenomenon.
Chemogenetic activation of VTA DA neurons has previously been used to demonstrate the
role of DA in mediating an increase in motivation for sucrose rewards.41 Our findings demonstrate
that enhancing VTA DA neuron activity is sufficient to prevent pain-induced decrease in
motivation, in both sucrose PR and the two-bottle choice behavioral task. Moreover, using CAV2cre in combination with Cre-dependent excitatory DREADDs, we show that activation of VTANAcSh pathway is sufficient to prevent pain-induced decrease in motivation for sucrose. While
this chemogenetic approach allows for a specific pathway activation, it is essential to acknowledge
that it does not allow for the cell specific activation within mesolimbic pathway, suggesting that
additional neuronal groups such as GABA or glutamate containing neurons could be contributing
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to this effect as well.33,42 Despite this, we found a significant positive correlation between the
number of DREADD infected DA neurons in the VTA and the percent motivation change in pain,
revealing a major impact of the specific DA population to recover motivation for sucrose in PR
task.
Prior studies have reported that the relief of the nociceptive component of ongoing pain is
sufficient to produce negative reinforcement through activation of the mesolimbic DA reward
pathway.34,43 Our data suggest that activating DA pathway reverses the induction of anhedonialike behavior but is not sufficient to relieve CFA-induced hyperalgesia. Together, these results
imply that removing the afferent nociceptive information produces negative reinforcement through
DA neurotransmission, while activating DA pathways helps to resolve the negative emotional
components of pain.
Previous evidence has established that DA release at the terminal level can be locally
modulated, independently from the DA cell firing, thus mediating different aspects of DA-related
behaviors.44 Therefore, while the excitability of DA cells is attenuated in pain, we found that the
ex vivo probability of local DA release at the axon terminals in the NAcSh remains unchanged.
The lack of effect of pain on the probability of DA release in the NAcSh could be due to the ex
vivo preparation of brain slices in which many inputs did not remain intact. These findings suggest
that pain-induced decrease in motivated behaviors is correlated with adaptations at the level of the
VTA DA neuron cell body. Although we show that pain does not affect the properties of DA
release at the terminals in NAc, other non-dopaminergic mechanisms have been shown to induce
adaptations in this brain area in pain; namely galanin receptor 1–triggered depression of excitatory
synaptic transmission in the NAc.22 Evidence from our laboratory among others has revealed
additional adaptations in the dynorphin and enkephalin NAc microcircuitry.21,22,45 While we did
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not find pain induced differences in the properties of terminal DA release in the NAcSh in an ex
vivo tissue preparation, we expanded our studies to an in vivo approach. Here we found that
chemogenetic stimulation of VTA DA terminals in the NAcSh prevents pain induced decrease in
motivation while CFA induced hyperalgesia remains intact. This result confirms the necessity of
enhanced activity of mesolimbic DA neurons in mitigating effects of pain on motivation.
Intake of drugs such as opioids is altered by the presence of pain.19 Specifically, pain
induces a rightward shift in dose response for opioid self-administration and attenuates opioidevoked DA release in NAc.19 The current findings further contribute to this line of evidence and
show that pain decreases consumption of natural rewards such as sucrose. This effect can be
overcome if the concentration of sucrose is increased, revealing a dose dependent shift in the
palatability and rewarding properties of natural rewards. Importantly, we demonstrate that water
consumption remains unchanged suggesting that the main effect of pain is on the perceived value
of sucrose solution. It has been postulated that the hedonic aspects of both drugs and natural
rewards are mediated through opioid systems in the brain.46,47 In fact, food consumption itself
releases endogenous opioids within mesolimbic pathway.46 Previous findings indicate that pain
induces dysfunction of MORs within VTA, thus leading to decreased motivation to obtain sucrose
rewards. Our current study demonstrates that increasing the concentration of sucrose rewards is
sufficient to overcome this effect, possibly by a mechanism that includes enhanced mesolimbic
endogenous opioid release.19,48
In conclusion, our results provide further understanding of pain’s regulation of the
mesolimbic DA pathway and its consequences on negative affect and in particular anhedonia-like
behaviors. It is essential to note that the observed decrease in motivation arises at the initial stages
of inflammatory pain and is one of the first symptoms of pain-induced negative affect. As such,
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further adaptations in the VTA DA circuits could still contribute to the development of paininduced depressive-like behaviors which arise at the later time points of persistent pain.40 We
propose that changes in the VTA DA pathways serve as a potential driver for alterations in circuits
mediating those behaviors. The present study uncovers adaptations in a key system necessary for
the affective component of pain.
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Chapter 3
Inhibitory tone from rostromedial tegmental nucleus onto
ventral tegmental area dopamine neurons is increased in
pain

This chapter contains previously unpublished data:
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Pain induces somatic adaptations in Ventral Tegmental Area Dopamine neurons to drive
anhedonia-like behavior. Nature Neuroscience, under revision.
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3.1 Abstract
Firing of dopamine (DA) neurons if tightly controlled by a balance of intrinsic activity and
synaptic input. The inhibitory GABA inputs represent a major synaptic input onto ventral
tegmental area (VTA) DA neurons, and this GABA inhibition of VTA DA neurons is reduced by
administration of mu opioid receptor (MOR) agonist. Previous evidence shows that MOR agonist
inhibition of GABA release onto VTA neurons is diminished in the presence of pain. In chapter 2,
we also demonstrate that inhibitory tone onto VTA DA neurons is increased in pain. However,
which GABA input is altered by pain remains to be elucidated. Using electrophysiology and
optogenetics we demonstrate that pain increases rostromedial tegmental nucleus (RMTg)
inhibitory tone onto VTA DA neurons. In addition, we were able to mimic the effects of pain on
sucrose consumption in naïve animals by chemogenomic stimulation of RMTg GABA showing
the sufficiency of this circuit to drive anhedonia-like behavior. Our findings uncover a circuit
mechanism mediating decrease excitability of VTA DA neurons in pain.
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3.2 Introduction
One of the main mediators of VTA DA neuron activity are inhibitory GABAergic inputs
which tonically inhibit VTA DA neurons.1–3 These inhibitory GABAergic inputs arise from the
rostromedial tegmental nucleus (RMTg), nucleus accumbens NAc, ventral pallidum (VP), and bed
nucleus of stria terminalis (BNST), among others, and make up a majority of the synaptic input.1–
4

Furthermore, RMTg GABAergic inputs are highly controlled by  opioid receptor system

(MOR).4,5 In fact, it is demonstrated that opioid drugs exert their reinforcing effects by binding to
MOR receptors on GABAergic terminals and disinhibiting VTA DA neurons. 6–8
Previous studies have shown that in the presence of inflammatory and nerve injury pain
GABAergic transmission in the VTA is dysregulated in response to MOR agonist application. 5,9,10
Namely, pain decreases MOR agonist ability to disinhibit VTA DA neurons. 9 This is also
demonstrated by attenuation of opioid evoked DA release in the NAc, the major projection site of
VTA DA neurons.9,10 It is likely that dysregulation of GABAergic transmission is responsible for
anhedonic states triggered by pain as well.
Indeed, evidence implicated the role of midbrain GABA neurons in driving aversive states.
To this end it has been reported that optogenetic activation of GABA neurons projecting onto
VTDA DA neurons is sufficient to drive conditioned place aversion (CPA). 11 In addition activation
of VTA GABAergic inputs disrupts reward consumption and serves as a signal of expected reward
suggesting a role in encoding of reward prediction error (RPE). 12 However, the contribution of
VTA DA projecting GABA neurons from different brain areas is driving aversive states is still
unclear.
Considering the sensitivity of RMTg GABA input onto VTA DA neurons to MOR
activation, and the fact that pain MOR system is downregulated in pain, in this chapter we focused
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to directly assess the contribution of inhibitory RMTg GABAergic inputs in mediating decreased
excitability of VTA DA neurons in pain.
Using patch-clamp physiology, optogenetics and chemogenetics we uncover that decrease
in VTA DA neuron excitability is at least in part associated with increased inhibitory drive from
GABAergic RMTg afferents, and that the stimulation of this pathway mimics the effects of pain
on sucrose consumption.
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3.3 Materials and Methods
Animals:
All procedures were approved by Washington University Committee in accordance with
the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Adult
male and female Long Evans GAD-cre rats (250-350g), were used for this study. All animals for
behavioral experiments were 8 to 10 weeks old at the beginning of the experiments. Animals used
for patch-clamp electrophysiology were 6 weeks old (injected with virus at 4 weeks old). Animals
were group housed with two to three animals per cage on a 12/12 hours dark/light cycle (lights on
at 7:00 AM) and acclimated to the animal facility holding rooms for at least 7 days before any
manipulation. All experiments were performed during the light cycle. Rats received food and water
ad libitum until 2 days prior to starting the behavioral studies, when food restriction (16 g of rat
chow per day) started and continued until the end of the experiments.
Surgeries:
All surgeries were performed under isoflurane (2.5/3 MAC) anesthesia using appropriate
sterile aseptic techniques.
Intra cerebral injections:
For chemogenetic activation of rostromedial tegmental nucleus (RMTg) GABA neurons
GAD-cre rats were bilaterally injected with either AAV5-hSyn-DIO-hM3D(Gq)-mCherry or
AAV5-Ef1a-DIO-mCherry (1.5-2.5x1012 transducing units per ml – 0.5μl per side) in the RMTg
(stereotaxic coordinates from Bregma: A/P =-6.8mm, M/L = ± 1.6mm, D/V = -8.4mm from skull
surface under 10 angle).
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For optogenetic electrophysiology recordings 4-week-old GAD-cre rats were injected bilaterally
with AAV5-EF1a-DIO-ChR2-eYFP in the RMTg (stereotaxic coordinates for viral injections from
Bregma: A/P =-6.3mm, M/L = ± 1.4mm, D/V = -7.4mm from skull surface under 10 angle).
To avoid post-surgical complications and minimize pain, animals received a daily
subcutaneous (s.c.) injection of 8mg/kg enrofloxacin and 5mg/kg carprofen solution for 2
consecutive days together with complementary carprofen chewable tablets. Behavioral
experiments were started 3 weeks after intracerebral injections to allow for maximal viral
expression at the time of testing.
Complete Freund’s Adjuvant (CFA) injections:
Animals were sedated using isoflurane anesthesia. Once appropriate sedation was
achieved, as determined by lack of reflex during toe-pinch, rats were injected in the right hindpaw
with 200 μl of CFA solution (Thermo Fisher), respectively. Saline injected animals served as
controls. Animals’ general behavior (feeding, drinking, locomotion) was monitored throughout the
duration of experiments.
Patch-clamp electrophysiology:
To record RMTg evoked inhibitory post-synaptic currents (IPSCs) onto VTA DA neurons,
VTA slices were prepared two weeks following viral injection of channelrhodopsin (ChR2) into
RMTg of GAD-cre rats and 2 days after the CFA/SAL injection. VTA DA neurons were voltage
clamped at -60 mV with the patch pipette internal solution containing (in mM): 100 KCl, 30
potassium gluconate, 4 MgCl2, 10 phosphocreatine disodium salt, 3.4 Na2ATP, 0.1 Na3GTP, 1.1
EGTA, and 5 HEPES. Activation of ChR2-expressing RMTg terminals was accomplished by an
LED mounted in the epifluorescence light path. Light power was modulated to the lowest intensity
at which we could consistently evoke a post-synaptic response, up to a maximum of 15 mW. IPSCs
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were isolated by the addition of the glutamate receptor antagonist kynurenic acid (2mM) to the
aCSF. Responses to paired stimuli were assessed at interleaved inter-stimulus intervals of 50, 100,
and 200 ms. Paired-pulse ratio (PPR) was calculated as the amplitude ratio IPSC2/IPSC1.
Recordings from saline- and CFA-treated pairs of rats were interleaved within each day
Two-bottle choice:
For the two-bottle choice studies, animals were water-restricted to four hours of water
access following the experimental session. For testing sessions, rats were individually placed in a
cage with no bedding and free access to either water or sucrose solutions placed on top of the wire
rack covering the cage. Water and sucrose solution bottle placement (right or left) was
counterbalanced. After 4 daily 1-hour habituation sessions during which animals were exposed to
water and a 5% sucrose solution, a baseline measurement of water and sucrose (60%) consumption
was obtained. Forty-eight hours after baseline session, another test was conducted to determine the
impact of chemogenetic enhancement of RMTg GAB neurons on sucrose consumption. CNO
(1mg.kg-1 s.c.) was injected 20 minutes prior to starting a two-bottle choice testing session. All
measurements for water and sucrose consumption were recorded as volume (ml) and amount (g)
of liquid consumed. After the two-bottle choice test with 60% sucrose was conducted, same set of
animals underwent second rout of test with 5% sucrose.
Immunohistochemistry:
Following behavioral experiment, rats were trans-cardially perfused with phosphate
buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were collected and kept
at 4ºC for 24h in 4% PFA for post-fixation, followed by 72h incubation in 30% sucrose solution.
Isopentane was used to flash freeze brain tissue which was consequently cut in 40 µm coronal
slices using a cryostat (Leica CM 1950). Free-floating sections containing RMTg were washed in
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PBS and blocked with Normal Donkey Serum (Millipore, S30) and 0.3% Triton-0.01 M PBS
(PBS-T) and incubated overnight in 3% normal donkey serum and 0.3% PBS-T containing GAD67
(mouse anti-GAD67, 1:5,000; MAB5406, EMDMillipore, Billerica) and mCherry (1:500; rabbit
anti- mCherry, ab167453). The following day, sections underwent a series of steps for Tyramide
Signal Amplification (1 hr streptavidin-horseradish peroxidase, 15 min TSA-biotin using a TSA
kit (Perkin Elmer). Sections were rinsed and then incubated with Streptavidin AF488 for GAD67
(1:200, Jackson ImmunoResearch) and AF568 for mCherry (Jackson ImmunoResearch)
visualization. A Leica DMR microscope was used to process images (5x,10x and/or 20x
magnification) of viral expression.
Analysis:
All experiments were performed at least twice, including each treatment condition to
prevent an unspecific day/condition effect. Treatment groups were randomly assigned to animals
prior to testing. After assessing the normality of sample data using Shapiro-Wilk test, statistical
significance was taken as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, as determined
by two - way repeated-measures ANOVA followed by two tailed Sidak post hoc test, and
Dunnett’s multiple comparisons test,
All data are expressed as mean ± SEM. Sample sizes (N number) always refers to value
obtained form an individual animal in all behavioral experiments (Figures 2, 3) or individual cell
recordings (Figure 1). Statistical analysis was performed in GraphPad Prism 8.1.0.
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3.4 Results
RMTg GABAergic neuronal projections onto VTA DA neurons exhibit higher release
probability in pain.
Inhibition of VTA DA neurons is known to disrupt reward consumption.12 Furthermore,
the activity of VTA DA neurons is highly controlled by synaptic inputs ono them.4,13,14 In the
chapter 2 we reveal that the inhibitory drive onto VTA DA neurons is increased in the presence of
pain, making DA cells less excitable. However, the anatomical origin of the GABAergic afferent
mediating this effect remains to be determined.
One of the main sources of inhibitory drive onto the VTA DA neurons is the rostromedial
tegmental nucleus (RMTg).2,12,15 In addition, RMTg represents the major opioid sensitive GABA
input onto VTA DA neurons.4 Interestingly, previous work from our lab demonstrated that mu
opioid receptor (MOR) mediated inhibition of GABA release in the VTA is diminished in pain.9
Thus, we hypothesized that the RMTg GABA input onto VTA DA neurons is enhanced in the
presence of pain.
To test this, we measured release properties of RMTg GABA neurons using paired-pulse
ratio (PPR). GAD-cre rats were injected with cre-dependent channel rhodopsin (AAV5-EF1aDIO-ChR2-eYFP) virus in the RMTg. After 2 recovery weeks to allow for appropriate viral
expression, animals received either CFA or SAL injection in the hindpaw (Figure 1 a). RMTg
evoked IPSCs onto VTA DA neurons were recorded ex vivo by activation of ChR2 expressing
RMTg terminals (Figure 1 b). Light power was adjusted to the lowest intensity at which we could
consistently evoke a post-synaptic response. We found that PPR was significantly depressed in
CFA treated animals as compared to saline-injected controls (Figure 1 c), demonstrating increased
release probability of RMTg GABA terminals onto VTA DA neurons. Further, PPR was not
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correlated with the evoked amplitude of initial response at any inter-pulse interval validating that
observed effect is not an artifact arising from potential vesicle depletion scaling with the efficiency
of channelrhodopsin (Figure 1 d). This finding uncovers an increased release probability of RMTg
GABA neurons onto VTA DA cells in pain.

Figure 1. RMTg GABAergic neuronal projections have higher release probability in CFA treated animals. a.
Representative image of viral injection in the RMTg and recording electrode in the VTA of GAD-cre animals. b.
Representative traces of evoked IPSCs in control (saline) and pain (CFA) condition. c. PPR is persistently depressed
in the condition of pain which is consistent with a higher release probability. (2way ANOVA for repeated measures;
inter-pulse interval: F3, 141 = 12.32, p<0.0001; interaction (inter-pulse interval x treatment): F3,141 = 2.479, p=0.0637;
Dunnett’s multiple comparisons post hoc test comparing PPR at each inter-pulse interval to the baseline: SAL,
*p=0.0363; CFA, **p= 0.0022; ***p=0.0009; **** p<0.0001, n (SAL) = 24 cells from 4 rats, n (CFA) = 25 cells
from 3 rats) d. PPR is not correlated with the evoked amplitude of initial response at any inter-pulse interval.
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Chemogenetic enhancement of RMTg GABA neurons mimics the effect of pain in two-bottle choice
test
To assess whether RMTg mediated inhibition of VTA DA neurons would mimic the effects
of pain on voluntary sucrose consumption we activated RMTg GABA neurons using a
chemogenetic approach during a two-bottle choice experiment. Cre-dependent excitatory
DREADDs (AAV5-hSyn-DIO-hM3D(Gq)-mCherry) or control virus (AAV5-Ef1a-DIOmCherry) were bilaterally injected in the RMTg of GAD-Cre rats (Figure 2 e, f and Figure 3 c,
d).
After habituation sessions of two-bottle choice, a baseline test was performed during which
both 60% sucrose and water volume consumed were recorded. To maintain consistency with the
pain two-bottle choice experiments animals were tested again forty-eight hours later, when they
also received subcutaneous administration of CNO (1mg.kg-1 s.c.). A week later animal underwent
additional baseline and post-CNO sessions using a 5% sucrose concentration in two-bottle choice
test (Figure 2 e).
We observed that activation of RMTg GABA neurons is sufficient to induce a decrease in
consumption of both, 60% and 5% sucrose solution (Figure 2 g, i, k). Importantly, the volume of
water consumed or the preference for sucrose solution remained unchanged upon activation of
RMTg GABA neurons (Figure 2 h, j and Figure 3 a,b). This finding shows that enhancing
inhibitory drive onto VTA DA neurons induces a decrease in consumption of 5% sucrose solution,
similar to pain-induced anhedonia-like states. In addition, we also report decreased consumption
of 60% sucrose, demonstrating the role of RMTg GABA neurons in reward processing. Taken
together these findings reveal that pain exerts increased inhibitory drive from RMTg GABA
neurons onto VTA DA neurons leading to anhedonia-like states.
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Figure 2. Chemogenetic activation of RMTg GABAergic neurons mimics the effects of pain on sucrose
consumption. a. Schematic representation of behavioral methodology. b. Representative coronal section of RMTg
Gq DREADD expressing neurons. Blue – DAPI; Red – m-Cherry (Gq DREADD); Green – GAD 67 (GABA neurons).
c. Activation of GABA containing neurons in the RMTg induces decrease in the amount of 60% sucrose consumed
(open bars -baseline, filled bars – 48 hours post CNO. 60% two-way ANOVA for repeated measures, time: F1,
11=4.816, p=0.0506; interaction (time x treatment): F1, 11=2.786, p=0.1233; Sidak’s post hoc within group: hM3Dq
(n=7) baseline versus 48 hours post CNO, * p=0.0317). d. Chemogenetic activation of RMTg GABA cells does not
alter consumption of water in 60% two-bottle choice test. i. Activation of GABA containing neurons in the RMTg
induces decrease in the amount of 5% sucrose consumed (open bars -baseline, filled bars – 48 hours post CNO. 5%
two-way ANOVA for repeated measures, time: F1, 11=0.3548, p=0.5635; interaction (time x treatment): F1, 11=10.96,
p=0.0069; Sidak’s post hoc within group: hM3Dq (n=7) baseline versus 48 hours post CNO, * p=0.03). f. Chemogenetic
activation of RMTg GABA cells does not alter consumption of water in 5% two-bottle choice test. g. Sucrose
consumption presented as percent change of baseline (5% sucrose two tailed unpaired t test, * p=0.0105; 60% sucrose
two tailed unpaired t test p=0.0610). The data are presented as the mean ± s.e.m.
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Figure 3. Chemogenetic stimulation of RMTg
GABA neurons does not alter sucrose preference
in two-bottle choice test. a-b. Chemogenetic
activation of RMTg GABA cells does not alter
preference for 60% or 5% sucrose in two-bottle
choice test. c. Representative coronal section of
RMTg Gq DREADD expressing neurons. Blue –
DAPI; Red – m-Cherry (Gq DREADD); Green –
GAD 67 (GABA neurons). d. Spread of overlay of
individual animal viral expression across RMTg in
DREADD and control m-Cherry injected GAD-cre
animals.
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3.5 Discussion
RMTg represents the major opioid sensitive inhibitory input onto VTA DA neurons 2,4 and
a potential mechanism by which VTA DA neurons are less responsive in pain. Indeed, we reveal
that RMTg GABA inputs are an important circuit mechanism through which VTA DA neurons
are less excitable in pain. This synaptic mechanism is bolstered by our behavioral results where
we demonstrate that enhancing inhibitory drive by chemogenetic activation of RMTg GABA
neurons decreases consumption of a lower concentration of sucrose solution, thus mimicking the
effects of pain. Interestingly, while pain does not affect intake of high concentration of sucrose
rewards, chemogenetic activation of RMTg GABA neurons decreases consumption of 60%
sucrose as well. One explanation for this finding could be that the chemogenetic approach we
employed leads to global activation of RMTg GABA neurons, while pain only impairs a subset of
RMTg GABA neurons, such as those containing MOR.4,9,10
While pain increases the probability of release of RTMg GABA neurons, it is crucial that
future studies ass the assess the effects of pain on GABA afferents onto VTA DA originating from
other brain areas such as those from NAc and VP. Previous studies have demonstrated that both
dopamine receptor 1 (D1) and dopamine receptor 2 (D2) neurons containing medium spiny
GABAergic neurons (MSN) in the NAc are altered by pain states. 16–18 Interestingly, both D1 and
D2 MSNs project back to the VTA either directly (D1) or indirectly via VP (D2). 19–21 In addition,
both of these areas are rich in kappa opioid receptor (KOR) which mediate aversive behaviors and
are shown to be upregulated in pain condition.17,22–24 Nonetheless, we conclude that RMTg GABA
afferents to the VTA DA neurons are an important circuit mechanism by which pain regulates
neurotransmission within mesolimbic DA pathway and exerts its consequences on negative affect
and in particular anhedonia-like behaviors.
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Chapter 4
Dissecting the role of dorsal hippocampus in contextual cueinduced reinstatement of drug seeking

This chapter contains previously unpublished data:
MARKOVIC T., MASSALY N., YOON K., FRYE H., SZE E., GARCIA J., YI J., MORÓN J.A.,
Dissecting the role of dorsal hippocampus in the reinstatement of drug seeking behavior. In preparation
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4.1 Abstract
Opioid use disorder is a chronic relapsing disorder encompassing misuse, dependence and
addiction to opioid drugs. Long term maintenance of associations between the reinforcing effects
of the drug and the environment in which they are administered are a leading cause of relapse.
Indeed, exposure to the “drug-environment” can lead to drug cravings and drug seeking behavior.
Numerous studies indicate that glutamatergic transmission in the dorsal hippocampus (dHPC) is
crucial for the formation of the learned associations between the rewarding effects of opioids and
the context in which they are given. In this chapter, we show that inhibiting excitatory dHPC
neurons during re-exposure to drug-context significantly attenuates drug-seeking reinstatement in
opioid self-administration. In addition, this inhibition did not alter either short term or long-term
memory as measured using the object location task. While these findings uncover the necessity of
dHPC in contextual cue-induced reinstatement of drug seeking, the exact afferents that are driving
enhanced activity of dHPC during contextual cue-induced reinstatement remain unknown. Future
experiments will focus on dissecting these afferents to the dHPC using viral approaches in
combination with cfos staining. Altogether, these studies will lead to a better understanding of the
neuronal circuits underlying context induced relapse in opioid-seeking behavior.
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4.2 Introduction
Opioid use disorder (OUD) represents an alarming national health issue. In 2019 alone
close to 50 000 people died from opioid overdose.1 Considering that it is chronic relapsing
disorder, people who are suffering from it are at risk of relapse. In fact, a study from 2010 reported
that up to 90% of opioid dependent patients relapsed over a period of time.2 Associations between
the effects of the opioids and the environment in which they are administered are a leading cause
of relapse as exposure to the environment leads to drug cravings and drug seeking behavior. In
order to find better treatment for OUD and prevent staggering relapse rates it is crucial to
understand the neural mechanisms driving reinstatement of drug-seeking behavior (relapse).
These long-lasting associations between opiates and the context in which they are taken
result in salient cues that lead to drug craving and ultimately relapse. Indeed, firing of dHPC is
modulated by reward predicting cues and encodes nicotine-reward contextual associations,
however whether that is true for opioid rewards is still unknown.3,4
The dorsal hippocampus (dHPC) has traditionally been recognized for its role in learning
and memory, but recent evidence also supports its role in the behavioral effects of opiates.5–8 These
evidence indicate that alterations of glutamatergic transmission in the dHPC are crucial for
behavioral measures of context-dependent morphine treatment such as morphine conditioned place
preference (CPP).5,6 In addition, application of dopamine (D1) receptors antagonist in the dHPC
abolished morphine CPP, suggesting that at least in part morphine reward is mediated by dopamine
(DA) inputs onto dHPC.9
One of the recently discovered outputs of dHPC neurons is the nucleus accumbens (NAc),
a key area for processing of cue-predicted reward related behaviors.10,11 Stimulation of this
pathway results in increased level of DA in the NAc, while optogenetic inhibition prevents sucrose
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CPP.10,11 These finding’s not only show the connectivity between these two areas but also that the
intact activity of dHPC is necessary for expression of reward-related memories.
Given its role in mediating morphine CPP and the anatomical connectivity with brain areas
known for the processing of reward related behavior we assessed the role of dHPC in contextual
cue-induced reinstatement of opioid seeking. Here we demonstrate that silencing excitatory dHPC
neurons during re-exposure to opioid-context significantly attenuates drug-seeking behavior,
without altering either short term or long term memory as measured using an object location task.
Future studies fill further dissect the inputs onto dHPC, using viral approaches, chemogenetics and
cfos staining as a measure of neuronal activity, to uncover the circuitry driving contextual cueinduced reinstatement.
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4.3 Materials and Methods
Animals:
All procedures were approved by Washington University Committee in accordance with
the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Adult
male and female WT Long Evans rats (250-350g) were used for this study. All animals for were 8
to 10 weeks old at the beginning of the experiments. Animals were group housed prior to jugular
vein catheter implant surgery with two to three animals per cage on a 12/12 hours dark/light cycle
(lights on at 7:00 AM) and acclimated to the animal facility holding rooms for at least 7 days
before any manipulation. After the catheter has been implanted animals were single housed to
prevent damage to the implants. All experiments were performed during the light cycle. Rats
received food and water ad libitum until 2 days prior to starting the behavioral studies, when food
restriction (16 g of rat chow per day) started and continued until the end of the experiments.
Surgeries:
All surgeries were performed under isoflurane (2.5/3 MAC) anesthesia using appropriate
sterile aseptic techniques.
Intracerebral injections:
For chemogenetic inhibition of dorsal hippocampus (dHPC) excitatory neurons WT rats
were bilaterally injected with either AAV5-CaMKIIa-hM4D(Gi)-mCherry or AAV5-Ef1a-DIOmCherry (1-2.5x1012 transducing units per ml – 0.5μl per side) in the dHPC (stereotaxic
coordinates from Bregma: A/P =-2.92mm, M/L = ± 2.0mm, D/V = -2.6mm from skull surface).
Jugular vein catheter implantation:
For intravenous (IV) self-administration (SA), animals were implanted with sterile
catheters in the right jugular vein. Catheter was kept in place with sutures and connected to harness
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placed over animals’ torso. Harness allowed for minimal stress while connecting and
disconnecting the animal from infusion lines. Catheter was kept patent by daily infusions of
gentamycin and saline (1.5 mg/ml intravenous).
To avoid post-surgical complications and minimize pain, animals received a daily
subcutaneous (s.c.) injection of 8mg/kg enrofloxacin and 5mg/kg carprofen solution for 2
consecutive days together with complementary carprofen chewable tablets. Behavioral
experiments were started either 2 weeks after intracerebral injections (or 1 week after the jugular
catheter implantation) to allow for maximal viral expression at the time of testing.
Operant intravenous self-administration:
Rat sucrose self-administration (SA) was conducted using operant-conditioning chambers
(Med Associates) equipped with two retractable levers positioned on the right-hand wall and a
food magazine connected to a food pellet dispenser between them. Two cue lights were positioned
above the levers, and one house light was positioned on the top left-hand wall. During selfadministration sessions both levers (correct and incorrect) were extended out with white cue light
turned on only above correct lever. Presses on the correct lever resulted in reward delivery and a
20 s time-out period during which correct and incorrect lever were retracted, and cue light above
correct lever was turned off. Presses on the incorrect lever did not result in any changes in the
environment. First, animals were placed in operant boxes under fixed ratio (FR) 1 schedule of
reinforcement for at least 5 sessions of sucrose SA lasting 2 hours or until the rat reached a
maximum of 60 rewards.
Following the training with sucrose rewards and jugular catheter implantation rats were
started on 2 hours daily acquisition sessions of 1.5 mg/kg/infusion morphine SA. The first 11 days
animals were placed in the SA boxes and the catheter line was connected to the line delivering
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drug infusions via pump upon correct lever presses. Animals were first trained on FR 1 schedule,
followed by 3 sessions of FR2 and 3 sessions of FR5. After the last FR5 session animals were
started on extinction.
For contextual cue-induced reinstatement experiment animals were placed on 10 days of 1
hour long extinction sessions where cue above the correct lever was off, rats were not tethered to
catheter line and the sound of the pump was off. Presses on both correct and incorrect levers were
recorded however no presses resulted in infusions of the drug. Following the last extinction session
animals were placed in the 1 hour session of contextual cue-induced reinstatement during which
cues associated with drug availability were on; light above correct lever was back on, animals were
tethered to the infusion lines and pump sound was back on. Presses on both correct and incorrect
levers were recorded however no presses resulted in infusions of the drug.
For drug primed reinstatement experiment animals were placed on 10 days of 1 hour long
extinction sessions where cue above the correct lever was on, rats were not tethered to catheter
line and the sound of the pump was on. Presses on both correct and incorrect levers were recorded
however no presses resulted in infusions of the drug. Following the last extinction session animals
were placed in the 1 hour session of drug-primed reinstatement during. 10 minutes prior to the start
of the reinstatement animals were injected subcutaneously (s.c.) within priming doses of fentanyl
(1 g/kg, 1.25 g/kg, 1.5 g/kg, 2 g/kg, and 4 g/kg) and saline s.c for control. During the drugprimed reinstatement cues light above correct lever and pump sound remained on but no presses
resulted in drug delivery. Presses on both correct and incorrect levers were.
For chemogenetic inhibition of dHPC 1 mg/kg s.c. injections of clozapine-N-oxide (CNO),
or saline for control animals, were administered 15 minutes prior to the start of the reinstatement
session.
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Immunohistochemistry:
Following behavioral experiment, rats were trans-cardially perfused with phosphate
buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were collected and kept
at 4ºC for 24h in 4% PFA for post-fixation, followed by 72h incubation in 30% sucrose solution.
Isopentane was used to flash freeze brain tissue which was consequently cut in 40 µm coronal
slices using a cryostat (Leica CM 1950). Free-floating sections containing dHPC were washed in
PBS and blocked with Normal Donkey Serum (Millipore, S30) and 0.3% Triton-0.01 M PBS
(PBS-T) and incubated overnight in 3% normal donkey serum and 0.3% PBS-T containing
mCherry (1:500; rabbit anti- mCherry, ab167453, Abcam). The following day, sections were again
rinsed with PBS and then incubated (2 hours) with the appropriate secondary antibodies (Jackson
ImmunoResearch). A Leica DMR microscope was used to process images (10x and/or 20x
magnification) of viral expression.
Object location test:
Object location test (OLT) involves five days of habituation (Day 1-5), one day of training
and short-term memory (STM) test (Day 6), and one day of long-term memory (LTM) test (Day
7). Animals were allowed to acclimatize for at least 30 minutes before testing in the room. At the
beginning of each session animals were placed in the center of the OLT arena and animals’
behavior was recorded using AnyMaze behavioral tracking software (Stoelting Co.)
During habituations sessions animals were placed in the OLT boxes for 10 minutes to
freely explore the environment. Following the last habituation session animals underwent 10
minutes training session where two identical objects were placed in the OLT arena. One hour after
the training session STM test was conducted during which one of the objects (variable object) was
moved to the other side of the box. Twenty-four hours after the training session animals underwent
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the LTM test during which variable object was moved again to a separate location from training
session and STM test. The moved objects were counterbalanced within experimental groups.
Boxes were cleaning using Cavicide between each animal, and bedding was altered between
animals of different sexes.
For chemogenetic inhibition of dHPC 1 mg/kg s.c. injections of clozapine-N-oxide (CNO),
or saline for control animals, were administered 30 minutes prior STM and/or LTM test.
For testing phases, the time spent interacting with each of the objects is measured.
Interaction with objects is measured when the animals’ nose is within 2.5 cm of the object and the
animal is facing the object (i.e. sniffing the object). This was measured automatically using AnyMaze and verified by the experimenters blinded to the treatment groups.
Analysis:
All experiments were performed at least twice, including each treatment condition to
prevent an unspecific day/condition effect. Treatment groups were randomly assigned to animals
prior to testing. After assessing the normality of sample data using Shapiro-Wilk test, statistical
significance was taken as ****p < 0.0001, as determined by two - way repeated-measures ANOVA
followed by two tailed Sidak post hoc test.
All data are expressed as mean ± SEM. Sample sizes (N number) always refers to value
obtained form an individual animal. Statistical analysis was performed in GraphPad Prism 8.1.0.
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4.4 Results
Drug-primed versus contextual cue-induced reinstatement
To study the neural mechanism behind drug-primed versus contextual cue-induced
reinstatement we utilized drug self-administration (SA) (Figure 1). This is a traditional model for
studying addiction like behavior in rodents, due to its ability to mimic several components of the
addiction cycle: acquisition, maintenance, and reinstatement.12,13 During acquisition of drug intake
animals were given daily 2 hours sessions of 1.5 mg/kg/infusion of morphine SA (correct lever
press results in morphine infusion) where the cue light above the correct lever indicated the
availability of the reward. Animals were trained on fixed ratio 1 (FR1 – 1 lever press results in an
infusion), followed by FR 2 (2 lever presses result in an infusion) and FR 5 (5 lever presses result
in an infusion) (Figure 2 a and Figure 3 a). In order to maintain stable hedonic state induced by
morphine infusion animals are expected to increase the number of lever presses as the FR
schedules increases. Indeed, we found that the number of correct lever presses increased
proportionally to the FR schedule of reinforcement to obtain the infusion of morphine, resulting in
consistent number of morphine infusions during the acquisition phase (Figure 2 b, c and Figure
3 b). The number of incorrect lever presses did not alter. Following the last acquisition session
animals underwent 10 days of 1 hour long extinction sessions.
In preliminary contextual cue-induced reinstatement experiment all the cues associated
with morphine availability were removed or turned off and no drug infusions occurred upon lever
press. This resulted in increased drug seeking during the first few days of extinction as measured
by increased number of correct lever presses (Figure 2 d). However, animals decreased their
responding over time, such that at the last day of extinction the lever number of presses on correct
and incorrect lever were similar (Figure 2 d).
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The following day animals were placed in the boxes and the contextual cues associated
with reward availability were re-introduced. This re-exposure to the cues successfully induced
reinstatement of drug seeking as compared to the last day of extinction (Figure 2 e). In control
group that did not have cues re-introduced during reinstatement no such increase was observed
(Figure 2 e). Here we were able to demonstrate successful contextual cue-induced reinstatement
of drug seeking behavior following morphine SA.
For the extinction in preliminary drug-primed reinstatement experiment the cues associated
with reward were present, but no lever press led to morphine infusion. Similarly, as above, this
resulted in enhanced drug seeking behavior during the first few days of extinctions which was
gradually diminished (Figure 3 c). We first aimed to induce reinstatement by s.c. injection of
morphine. However, at this point animals have developed tolerance upon chronic morphine
exposure during acquisition which resulted in animals’ inability to interact with the lever. In order
to avoid locomotor impairment induced by tolerance to morphine we utilized a s.c. injection of the
short acting opioid fentanyl instead. While fentanyl induced reinstatement of drug-seeking in a
dose dependent manner (Figure 3 d), the concern that cross-interaction between two different
opioids is not well known or how it affects neural circuits, we focused on investigating the
necessity of the dHPC in contextual-cue induced reinstatement for the rest of this chapter.

Figure 1. Behavioral schematic of drug-primed and contextual-cue induced reinstatement of drug seeking.
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Figure 2. Contextual cue-induced reinstatement of drug seeking. a. Behavioral schematic of experimental design.
b. Animals maintain drug-taking as the schedule of reinforcement increases. c. Number of infusions remain stable
during acquisition. d. Drug seeking behavior is extinguished after 10 days of extinction. e. Re-exposure to cues
reinstates drug-seeking behavior. The control animals that did not have cues on during reinstatement did not display
drug-seeking behavior.
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Figure 3. Fentanyl primed reinstatement of drug seeking. a. Behavioral schematic of experimental design. b.
Animals maintain drug-taking as the schedule of reinforcement increases. c. Drug seeking behavior is extinguished
after 10 days of extinction. d. Fentanyl dose-dependently induces reinstates drug-seeking behavior.
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Inhibition of excitatory dHPC attenuates contextual cue-induced reinstatement of drug-seeking
After establishing the protocol for contextual cue-induced reinstatement we next assessed
the role of dHPC in this behavior. In order to selectively inhibit dHPC excitatory neurons we
bilaterally injected inhibitory Designer Receptors Exclusively Activated by Designer Drugs
(DREADDs) AAV5-CaMKIIa-hM4D(Gi)-mCherry or control virus AAV5-Ef1a-DIO-mCherry
in the dHPC of WT rats (Figure 4 a, b). Similarly, to above-described experiments we successfully
established acquisition of morphine SA, followed by extinction during which animals extinguished
drug-seeking behavior. (Figure 4 c, d) After the last day of extinction, animals were re-exposed
to the contextual cues associated with reward availability. We found that inhibition of excitatory
dHPC neurons attenuated contextual cue-induced reinstatement of drug seeking behavior (Figure
4 e). This effect is specific to the inactivation of dHPC neurons by DREADDs as our control
animals injected with control virus or DREAD ligand clozapine-N-Oxide (CNO) alone showed
robust reinstatement to re-exposure to the contextual cues (Figure 4 e).
To assess whether inhibition of dHPC specifically mediates opioid related memory we
employed the same chemogenetic strategy in the processing of spatial memory using object
location test (OLT) with two identical neutral objects.14 In these preliminary studies we tested
whether inhibition of dHPC alter short-term (STM) or long-term memory (LTM), by measuring
the amount of time animal spends interacting with moved object (discrimination index) (Figure 5
a). Interestingly, we did not find an effect of the dHPC inhibition on either STM or LTM when
CNO was administered right before the two tests (Figure 5 b). However, we found that inhibition
of dHPC during STM affected LTM the following day (Figure 5 b).
Briefly, our results indicate that the activity of dHPC is necessary for expression of
contextual cue-induced reinstatement of drug seeking. We confirm that this effect is not due to an
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overall impairment of memory recall as animals in which excitatory dHPC neurons were silenced
performed similarly to control animals in OLT, although additional experiments will focus on
replicating these findings and increasing the number of animals tested.

Figure 4. Inhibition of dHPC attenuates contextual cue-induced reinstatement of drug-seeking. a. Behavioral
schematic of experimental design. b. Verification of viral expression in dHPC (blue-DAPI, red-mCherry). c. Number
of lever presses during morphine acquisition. Number of correct lever presses increased with the schedule of
reinforcement while infusions of morphine stayed consistent. d. Number of lever presses steadily decreases over the
10 extinction sessions. At the end of the extinction no discrimination between the correct and incorrect lever is present.
e. Number of lever presses during the last day of extinction and contextual cue-induced reinstatement. Chemogenetic
inhibition of dHPC during reinstatement attenuates contextual cue-induced drug-seeking. (two-way ANOVA for
repeated measures, time: F1, 41 = 49.94, p<0.0001; interaction (time x treatment): F2, 41 = 9.565, p=0.0004; Sidak’s post
hoc between last day of extinction and reinstatement within group comparison, **** p<0.0001).
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Figure 5. Inhibition of dHPC does not affect memory retrieval in object location test. a. Behavioral schematic of
experimental design. b. Discrimination index for the moved object in object location test. Animals displayed no
preference for either object on training day. Chemogenetic inhibition of dHPC 30 minutes prior to short term memory
test did not alter animals’ discrimination index as compare to control animals. Similarly, inhibition of dHPC 30
minutes prior to long term memory test did not affect animals’ preference for the moved object. However, long term
memory processing was altered in animals whose hippocampus was inhibited during the short term memory task.
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4.5 Discussion
With the continuous rise in OUD in the USA it is of utmost importance to develop better
strategies to curb the ongoing epidemic. One of the approaches to prevent the increase of the
mortalities in OUD is by preventing the staggering rates of relapse.15–17 To address this issue, we
must first start by understating the neurobiology involved in relapse or reinstatement of drugseeking behavior.
Previous studies implicated the role of dHPC in opioid related behaviors using the
conditioned place preference paradigm for opioid drugs. 5,9,18 While this behavioral paradigm is
well suited to assess the associative learning between rewarding properties of opioids and the
context in which they are given, its main limitation is that animals are not voluntarily administering
opioids. Thus, in order to assess the role of dHPC in reinstatement of opioid-seeking we decided
to utilize the operant self-administration procedure, where the animal voluntarily lever presses for
opioid infusions. In preliminary studies we demonstrate that we can reliably induce opioid seeking
by re-exposure to the contextual cues associated with opioid availability. Using this approach, we
report that chemogenetic inhibition of excitatory dHPC neurons attenuates contextual cue-induced
reinstatement, demonstrating the necessity of this area in driving seeking for the opioid drug.
Interestingly, previous evidence demonstrate that activity of dHPC projections to lateral septum
are necessary for contextual (represent drug availability) but not cue (represent drug taking)
induced reinstatement of cocaine seeking, indicating that this area is involved in cocaine seeking
as well.19 Taken together, these findings suggest that dHPC is involved in encoding the learned
association between rewarding drugs and context which signal drug availability, making it an
important mechanism for the recall of those memories and reinstatement of drug-seeking.
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It is known that dHPC also mediates memory processing, thus silencing the activity of this
brain area could lead to overall memory deficits. Therefore, we assessed whether the attenuation
of contextual cue-induced reinstatement is due to overall memory impairment using OLT. Here
we demonstrated that the memory recall during either STM or LTM was not affected by inhibition
of dHPC. However, inhibiting dHPC during SMT impaired memory consolidation as shown by no
discrimination for the moved object when testing was conducted the following day. While it may
be surprising that inhibiting dHPC does not alter memory recall in spatial object location test we
postulate that the lack of the effect is due to a neutral property of identical objects in this task.
Indeed, disruption of dHPC is shown to impair memory encoding and retrieval of memories
related to highly salient stimuli such as fear memories, or as shown in this chapter opioid related
memories.20
In conclusion, our data suggests that dHPC is necessary for opioid seeking in contextual
cue-induced reinstatement, and that observed attenuation of reinstatement upon inhibition of dHPC
is not due memory retrieval impairment but rather to a selective disruption of the drug-reward
association.
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Chapter 5
Further discussion and future experiments
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5.1 The importance of assessing negative affective component of pain in preclinical studies
While the ability to detect painful stimuli serves an evolutionary and protective role, the
maladaptive experience of pain results in debilitating consequences for human well-being and
health. Chronic and persistent pain are one of the most common reasons adults seek medical help.1
This serious disorder decreases the quality of life of patients, leading to a reduction in pre-pain
activities and development of negative affective states.2–4 One of the main complications that arises
in the treatment of pain patients is that current medications such as opioids have high abuse liability
and are not very effective in treating negative affective states.5,6
Although there is a significant need to develop more efficacious pharmacological
treatments devoid of abuse liability and side effects, no novel drugs have proven to be more
effective in the clinic yet.7 One of the main obstacles is the lack of preclinical studies on the
mechanisms underlying negative affective states in pain. Without understanding of the
mechanisms by which different types of pain lead to negative affect such as depression, anhedonia,
loss of motivation and anxiety therapeutic approaches to treat this significant component of pain
experience are not available yet.8
Chapters 2 and 3 of this dissertation aimed to dissect how a persistent inflammatory model
of pain affects the mesolimbic reward circuit, an area implicated in reward-related, aversive and
alerting behaviors, and how this act to drive anhedonic states induced by pain.9–13
5.2 Decrease in DA neurotransmission is necessary for reduction in motivation for selfadministration of sucrose pellets
Both clinical and preclinical studies have shown that presence of pain impairs motivated
responses to natural rewards.12,14,15 This pain-induced behavioral adaptation is highly correlated
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with a suppression in DA neurotransmission in the mesolimbic pathway, making it an ideal
candidate circuit to examine the mechanisms underlying

pain-induced negative affective

sates.12,16–18 We utilized ex vivo physiology and in vivo fiber photometry to dissect the specific
mechanisms underlying pain-induced decrease in mesolimbic DA neurotransmission.
Using ex vivo voltammetry we did not observe any significant differences between the pain
and control animals at the terminal level with either optically or electrically evoked DA release in
the NAc, suggesting that adaptations in DA system may happen at cell body level in the VTA and
could be better captured during the behaviors measuring negative affect.
To this end we utilized in vivo fiber photometry to assess DA cell activity in freely moving
animals during an operant task to examine motivated behavior for sucrose. We demonstrate that
overall rate of DA cell activity is diminished in pain, while phasic repose to the reward delivery is
enhanced. While increase in phasic response may be surprising at first, it could indeed be
correlated with changes in the hedonic state of the animal in pain. Briefly, previous findings have
reported that rewards of larger value than expected exert higher phasic DA response (known as
positive reward prediction error).19–21 In agreement with our findings, a decrease in overall VTA
DA activity during motivational behavioral task could be a signal of overall decrease hedonic state
of an animal. Thus, animal experiencing a lower hedonic state has lower expectation of reward (or
reward value). Once the animal receives the reward in such state it may then indeed be perceived
as a reward of higher value leading to the higher phasic VTA DA activity. Nonetheless, decreased
hedonic state persists as encoded by overall decrease in DA activity throughout the session.
Another explanation for this intriguing finding could be due to overall more inhibited state
of VTA DA neurons. Using patch-clamp electrophysiology we demonstrate decreased intrinsic
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excitability of VTA DA neurons resulting from increased inhibitory tone onto them. This inhibited
state of VTA DA neurons will then accentuate the phasic change of VTA DA neuron activity in
response to reward delivery. This is the limitation of the fiber photometry approach which we
aren’t able to more closely address with the current methods.
5.3 Release probability of GABAergic RTMg afferents onto VTA DA neurons is increased in pain
While decreased excitability of VTA DA has been previously reported in the nerve injury pain
condition, we demonstrate that inflammatory pain exerts similar effects making VTA DA cells
less excitable as well.22 We further expand the mechanistic insight into the observed pain-induced
decrease in excitability of VTA DA neurons.
To this end we show that, at least in part, increased inhibitory GABA tone onto VTA DA
cells is originated from one of the densest GABA projections, the RMTg. While other studies show
that additional inputs onto VTA DA neurons are altered in pain, such as excitatory inputs from
ventrolateral periaqueductal gray (vlPAG) onto non-DA VTA cells mediating aversiveness in
migraine model of pain, this is the first time that RMTg to VTA DA circuit has been implicated in
pain.23 Our finding provides a significant advance in understanding the circuitry behind negative
affective states in pan. Indeed, using chemogenetics we demonstrate that the activation of RMTg
GABA neurons mimics pain induced decrease of sucrose consumption in the two-bottle choice
test.23,24 Ongoing studies will uncover whether inhibiting RMTg-VTA GABA input is sufficient
to prevent this anhedonic-like state in pain.
5.4 Pain alters the reinforcing properties of sucrose rewards, proving an additional measure of
negative affect in preclinical studies
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Decrease in motivation for both natural and opioid rewards has been reported in both nerve
injury and inflammatory model of pain.12,13,17,18,25 In addition, this decrease in motivation for
opioid drugs can be overcome by increasing the concentration of the opioid, further demonstrating
impaired reward processing in pain. In this dissertation we show that not only motivation is
decreased in pain but also the hedonic processing of sucrose rewards. These anhedonic-like states
which are found in persistent pain patients are for the first time reported in animal models of
anhedonia using two-bottle choice.4,26 Using chemogenetics we further show that decreased
activity in the VTA DA neurons is necessary for reduction in sucrose consumption, implicating
the importance of this pathway in mediating pain induced anhedonia.
5.5 Chemogenetic stimulation of VTA DA neuron mitigates negative affective states without
altering nociceptive responses
It is well known that pain relief exerts DA release within VTA-NAc pathway, likely
through a process of negative reinforcement.27,28 However, using chemogenetic stimulation of
VTA DA neurons we demonstrate that enhanced release of DA does not produce pain relief in the
rat model of inflammatory pain. On the other hand, recent report suggests that activation of VTA
DA neurons produces pain relief in mice nerve injury model of pain.29 These findings further raise
an important point to keep in mind in the field that different pain models in different species can
have opposite effects in nociceptive behaviors.
While chemogenetic activation does not alleviate hyperalgesia, using this approach we
were able to restore the motivation and reinforcing responses to natural rewards thus mitigating
negative affective states in inflammatory pain. This finding provides an important discovery that
a decrease in VTA DA neuron activity is necessary to drive deficits in these behaviors. It further
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suggests that the circuits mediating nociceptive and affective component of pain may at least in
part be divergent.
5.6 Contribution of MOR system to enhanced GABAergic tone and downregulation of DA
neurotransmission in pain
Current data presented in this dissertation demonstrate that inhibitory tone from RMTg
afferents onto VTA DA neurons is enhanced in pain making DA neurons less excitable which is
correlated with decreased motivation and anhedonia-like behavior. Future studies will build on
this finding by assessing the contribution of MOR system to inhibition of VTA DA neuron.
There is some evidence from previous studies that MOR system is downregulated in both
nerve injury and inflammatory model of pain. Indeed, opioid disinhibition of VTA DA neurons is
diminished in pain leading to attenuation of opioid evoked DA release in NAc. 12,17 However,
whether the receptor function or the release of MOR endogenous ligand is altered in pain is not
known. To address this question future experiments will:
1. Measure release of endogenous MOR ligands enkephalin and endorphin in the VTA using
microdialysis in control and pain animals (in collaboration with Dr. Ream Al-Hasani lab
at Washington University in Saint Louis)
2. Measure the functionality of MOR in the VTA using receptor binding and signaling assays
(in collaboration with Dr. John Traynor lab at the University of Michigan)
3. Test whether intracranial injections of positive allosteric modulators (PAMs) can prevent
pain induced negative affective states by potentiating the activity of bound orthostatic
agonist (endogenous ligand of MOR) through increased potency and efficacy
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In addition to RMTg, another area rich in the MOR expression that mediates motivated
behavior and depressive-like states is lateral habenula (LHb).30–32 LHb is also known to process
nociceptive pain inputs.33 Interestingly, this area projects to both VTA and RMTg and could
represent an important hub where both nociceptive and affective component of pain are processed
and passed onto downstream targets.34–36
5.7 Curbing the opioid epidemic
As discussed in the introduction of this dissertation, the necessity for better pain management
strategies and the over-prescription of opioids for treatment of pain in the 90’s contributed in large
to the ongoing opioid use disorder (OUD) epidemic in the USA.37–39 In order to prevent increasing
rates of relapse and overdose deaths, better understating of the mechanism leading to drug craving
and drug-seeking behavior, in addition to better pain management strategies is necessary.
To this end in chapter 4 of this dissertation we uncovered the necessity of dorsal
hippocampus (dHPC) in driving reinstatement to contextual cue-induced reinstatement.
Furthermore, dHPC and its projections to lateral septum are important for mediating reinstatement
to cocaine seeking as well, suggesting a role of this area on overall substance use disorder. 40–42
However, which areas are driving the activity of dHPC leading to reinstatement are unknown.
Upcoming experiments will aim to answer this question using viral approaches and staining
for cfos as a marker on neuronal activity. Thus, retrograde virus carrying GFP tag will be injected
into dHPC to mark all the projections onto this area. Animal will then undergo contextual cueinduced reinstatement paradigm and the brain tissue will be processed following the reinstatement.
After staining for cFos we will determine which brain area shows highest level of cFos expression
as compared to animal that was not re-exposed to cues. We will then map the cFos expression onto
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areas projecting to dHPC and determine which area co-expresses GFP tag and has highest number
of cFos expressing neurons. We will use inhibitory chemogenetics to silence this pathway and
assess its effects on contextual cue-induced reinstatement.
In addition to dissecting the circuits mediating these behaviors, it is crucial to develop better
treatments for both pain patients and individuals suffering from OUD. To this end studies
presented in the appendix of this dissertation, done in collaboration with the lab of Dr. Robert
Gereau at Washington University in Saint Louis, and Dr. Tuan Trang at University of Calgary,
will assess potential new therapeutic approaches in managing pain devoid of abuse liability, and
mitigating withdrawal states following opioid self-administration to attenuate reinstatement of
drug-seeking.
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Appendix
New treatment approaches for pain management and
prevention of drug-seeking

Experiments in the appendix are part of the two collaborations (Dr. Robert Gereau and Dr. Tuan
Trang laboratories) whose manuscripts are in preparation
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A.1 Abstract
Pain crisis and opioid use disorder (OUD) are closely dependent on each other, as the
urgency for better treatment of pain lead to a steep rise in the prescription of opioid medications.
However, in persistent or chronic pain condition opioids are not as effective. In addition, new pain
patients with the history of OUD are even more challenging to treat. Thus, finding novel potentially
opioid-independent treatments for both pain and OUD is an important step in managing these two
challenging conditions. In this part of the dissertation, we propose the use of two novel approaches
for the treatment of pain and prevention of drug-seeking behavior: 1) the metabotropic glutamate
receptor 5 negative allosteric modulator VU238 for the treatment of pain which is devoid of
reinforcing properties thus possessing lower misuse liability 2) probenecid, a pannexin 1 channel
blocker for the prevention of contextual cue-induced reinstatement.
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A.2 Introduction
Pain and opioid use disorder represent major health concern in the United States of
America (USA).1–3 These debilitating disorders have reached epidemic proportions which resulted
in National Institute of Health (NIH) cross-agency efforts to tackle opioid epidemic through the
HEAL initiative by 1) assessing mechanisms underlying pain and developing better pain treatment
and 2) improving treatment for opioid misuse an addiction.4
Ideal medication for pain would alleviate both, sensory and negative emotional component
of pain, with minimal side effects and no misuse liability. In this aspect, metabotropic glutamate
receptor system (mGluR) has been considered as one of the possible targets for developing better
therapeuthics.5 Indeed, Fenobam (a mGluR5 negative allosteric modulator - NAM), a drug that
has been in clinical use for its anxiolytic properties, has shown to produce antinociception and
analgesia in both acute and nerve injury model of pain.6–8 However, in humans the plasma levels
of Fenobam and its antinociceptive properties were highly variable, which limited it’s clinical use
for pain.6 Therefore, developing mGluR5 NAMs with more desirable pharmacokinetic properties
is needed to move forward in clinical use. One of such compounds, VU238, has been developed
as a part the collaborative efforts between investigators at Washington University in Saint Louis
and Vanderbilt University.9 VU238 displayed a potent pain relief in formalin (acute) and nerve
injury (chronic) models of pain (data collected by members of Dr. Robert Gereau lab). However,
whether this compound, or Fenobam, exert any reinforcing properties is unknown. Study presented
in this dissertation demonstrates that, neither VU238 nor Fenobam induce drug-taking behavior in
naïve animals, as compared to pain reliving opioid drug Fentanyl. This behavioral outcome is
promising, although it requires further testing of its reinforcing properties in the condition of pain.
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In addition to mGluR5 NAMs, another promising avenue in pain management are pannexin
1 (panx1) channel blockers such as probenecid. Panx1 channels have been implicated in multiple
pathologies such as stroke, pain, inflammation and epilepsy.10 Indeed probenecid has been
successfully used for treatment of inflammatory joint pain conditions such as gout, in both
preclinical and clinical studies.11,12 Additionally, ablation of panx1 channels in macroglia, as well
as blocking of these channels using probenecid alleviated morphine withdrawal as shown in work
done by our collaborators in Dr. Tuan Trang lab.13 Considering its pain relieving properties and
reduction of withdrawal severity Probenecid could have a preventative effects in relapse of opioid
seeking as well.14 Indeed, our studies confirm that administration of Probenecid during the
extinction and/or reinstatement attenuates contextual cue-induced drug-seeking.
Taken together, non-opioid approaches such as mGluR5 NAMs or panx1 blockers, have a
promising effect in management of pain and prevention of drug-seeking, prompting future studies
of these drugs for assessment of possible side effects and success rate in treating negative affective
component of pain.
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A.3 Materials and Methods
Animals:
All procedures were approved by Washington University Committee in accordance with
the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Adult
male and female WT Long Evans rats for Probenecid studies and Sprague Dawley rats for
Fenobam and VU238 studies (250-350g) were used. All animals were 8 to 10 weeks old at the
beginning of the experiments. Animals were group housed prior to jugular vein catheter implant
surgery with two to three animals per cage on a 12/12 hours dark/light cycle (lights on at 7:00 AM)
and acclimated to the animal facility holding rooms for at least 7 days before any manipulation.
After the catheter has been implanted animals were single housed to prevent damage to the
implants. All experiments were performed during the light cycle. Rats received food and water ad
libitum until 2 days prior to starting the behavioral studies, when food restriction (16 g of rat chow
per day) started and continued until the end of the experiments.
Surgeries:
All surgeries were performed under isoflurane (2.5/3 MAC) anesthesia using appropriate
sterile aseptic techniques. For intravenous (IV) self-administration (SA), animals were implanted
with sterile catheters in the right jugular vein. Catheter was kept in place with sutures and
connected to harness placed over animals’ torso. Harness allowed for minimal stress while
connecting and disconnecting the animal from infusion lines. Catheter was kept patent by daily
infusions of gentamycin and saline (1.5 mg/ml).
To avoid post-surgical complications and minimize pain, animals received a daily
subcutaneous (s.c.) injection of 8mg/kg enrofloxacin and 5mg/kg carprofen solution for 2
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consecutive days together with complementary carprofen chewable tablets. Behavioral
experiments were started 1 week after the jugular catheter implantation to allow for full recovery.
Operant intravenous self-administration:
Rat sucrose self-administration (SA) was conducted using operant-conditioning chambers
(Med Associates) equipped with two retractable levers positioned on the right-hand wall and a
food magazine connected to a food pellet dispenser between them. Two cue lights were positioned
above the levers, and one house light was positioned on the top left-hand wall. During selfadministration sessions both levers (correct and incorrect lever) were extended out with white cue
light turned on only above correct lever. Presses on the correct lever resulted in reward delivery
and a 20 s time-out period during which correct and incorrect lever were retracted, and cue light
above correct lever was turned off. Presses on the incorrect lever did not result in any changes in
the environment.
For Probenecid studies animals were first placed in operant boxes under fixed ratio (FR) 1
schedule of reinforcement for at least 5 sessions of sucrose SA lasting 2 hours or until the rat
reached a maximum of 60 rewards. Following the training with sucrose rewards and jugular
catheter implantation rats were started on daily 2 hours acquisition sessions of 1.5 mg/kg/infusion
morphine SA. The first 11 days animals were placed in the SA boxes and the catheter line was
connected to the line delivering drug infusions via pump upon correct lever presses. Animals were
first trained on FR 1 schedule, followed by 3 sessions of FR2 and 3 sessions of FR5. After the last
FR5 session animals were started on extinction.
For contextual cue-induced reinstatement experiment animals were placed on 10 days of 1
hour long extinction sessions where cue above the correct ever was off, rats were not tethered to
catheter line and the sound of the pump was off. Presses on both correct and incorrect levers were
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recorded however no presses resulted in infusion of the drug. Following the last extinction session
animals were placed in the 1 hour long session of contextual cue-induced reinstatement during
which cues associated with drug availability were on; light above correct lever was back on,
animals were tethered to the infusion lines and pump sound was back on. Presses on both correct
and incorrect levers were recorded however no presses resulted in infusion of the drug. Probenecid
at the dose of 100mg/kg diluted in sterile saline was injected intraparietally i.p. 1 hour prior to
starting the animals in SA boxes either during extinction alone, during extinction and reinstatement
or during reinstatement alone.
For Fenobam and VU238 SA animals were placed in the SA boxes and the catheter line
was connected to the line delivering drug infusions via pump upon correct lever press. Animals
were started with 10 days of daily 2 hours session on FR 1 schedule for either of the compounds
tested - vehicle, fenobam, fentanyl and VU238. Following 10 days on FR1, animals were placed
on 3 days of FR2 and 3 days on FR5 to assess the reinforcing properties of different doses of
fenobam and VU238. Fenobam was diluted in 20% captisol as a vehicle, while VU238 was diluted
in 40% polyethylene glycol 400 (PEG-400) and 30% dimethyl sulfoxide (DMSO) as a vehicle.
Analysis:
All experiments were performed at least twice, including each treatment condition to
prevent an unspecific day/condition effect. Treatment groups were randomly assigned to animals
prior to testing. All data are expressed as mean ± SEM. Sample sizes (N number) always refers to
value obtained form an individual animal. Treatment groups were randomly assigned to animals
prior to testing. After assessing the normality of sample data using Shapiro-Wilk test, statistical
significance was determined by two - way repeated-measures ANOVA followed by two tailed
Sidak post hoc test. Data was visualized and analyzed in GraphPad Prism 8.1.0.
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A.4 Results
Both Fenobam and VU238 are mGluR5 NAMs shown to be antinociceptive and analgesic
in formalin induced and nerve injury pain models.6,9 However, their potential for misuse is
unknown. To address this, we tested their ability to reinforce drug-taking behavior in acquisition
of SA. Three antinociceptive doses of Fenobam and VU238 (0.1mg/kg/infusion, 0.3
mg/kg/infusion and 1mg/kg/infusion) were assigned to a separate group of animals. In addition,
we also tested SA of vehicle in which drugs were diluted, as well as fentanyl to serve as a
comparison of pain reliving drug that is a potent reinforcer and exerts high potential for misuse. 15
Using this approach, we discovered that neither Fenobam nor VU238 induce drug-taking behavior,
as the number of infusions did not differ than those of animals in vehicle groups (Figure 1 a, b).
In contrast, animals self-administering fentanyl (2 g/kg/infusion) diluted in appropriate vehicles
showed a robust acquisition of drug intake and maintained infusion numbers across FR1, FR2 and
FR5 schedule of reinforcement (Figure 1 a, b). This finding suggests that neither Fenobam nor
VU238 exert reinforcing properties in pain naïve animals.
In addition to uncovering safe pain reliving drugs, it is equally important to find treatments
for prevention of relapse (drug-seeking) in OUD. One such candidate is panx1 channel blocker
Probenecid, as it is shown to not only be antinociceptive and analgesic but has the ability to
attenuate morphine withdrawal.12,13 To assess the ability of Probenecid (100mg/kg i.p. injection
given one hour prior to testing sessions) to prevent drug-seeking behavior we utilized contextual
cue-induced reinstatement of opioid SA. Here we trained animals in morphine SA (1.5
mg/kg/infusion) followed by extinction and reinstatement (Figure 2 b and Figure 3 b). We show
that when given during extinction and reinstatement, or reinstatement alone Probenecid
significantly attenuates contextual cue-induce drug-seeking behavior (Figure 2 e and Figure 3 d).
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This is demonstrated by decreased number of lever presses associated with opioid delivery as
compared to control saline injected animals. Interestingly, if given only during the extinction
probenecid did not have an effect on contextual cue-induced reinstatement (Figure 2 d).
These findings demonstrate a promising target for development of novel therapies for safer
pain management and OUD treatment.

Fenobam SA

VU238 SA

a

b

Figure 1. Self-administration of mGluR5 NAM Fenobam and VU238. a. Fenobam does not induce drug-taking
behavior as measured by infusions comparable to that of vehicle group, which is opposite to a high number of infusions
in fentanyl group. b. Similarly, VU238 does not induce drug-taking behavior as well, suggesting that neither mGluR5
NAMs have reinforcing properties.
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a

1.5 mg/kg/infusion
morphine acquisition

PBC/SAL
Extinction
(cues off)

PBC/SAL or. No injection
Reinstatement
(cues on)

Figure 2. Continuous administration of Probenecid during extinction and reinstatement attenuates contextual
cue-induced drug-seeking behavior. a. Behavioral schematic of experimental design. b. Acquisition of morphine
SA, animals increase number of correct lever presses to obtain morphine infusions as schedule of reinforcement
increases. c. Number of lever presses steadily decreases over the 10 extinction sessions. At the end of the extinction
no discrimination between the correct and incorrect lever is present. Probenecid (100 mg/kg i.p.) does not alter the
rate of extinction. d. Administration of Probenecid during extinction alone does not alter contextual cue-induced
reinstatement (two-way ANOVA for repeated measures, time: F1, 21 = 34.95, p<0.0001; interaction (time x treatment):
F1,21 = 0.1765, p=0.6787; Sidak’s post hoc between last day of extinction and reinstatement within group comparison,
*** p<0.0001, ** p=0.0021). e. Continuous administration of Probenecid during extinction and reinstatement
attenuates drug-seeking behavior upon re-exposure to contextual cues (two-way ANOVA for repeated measures, time:
F1, 21 = 26.87, p<0.0001; interaction (time x treatment): F1,21 = 16.41, p=0.0006; Sidak’s post hoc between last day of
extinction and reinstatement within group comparison, **** p<0.0001).
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Figure 3. A single injection of Probenecid before the reinstatement test attenuates contextual cue-induced drugseeking behavior. a. Behavioral schematic of experimental design. b. Acquisition of morphine SA, animals increase
number of correct lever presses to obtain morphine infusions as schedule of reinforcement increases. c. Number of
lever presses steadily decreases over the 10 extinction sessions. At the end of the extinction no discrimination between
the correct and incorrect lever is present. d. Administration of Probenecid during reinstatement test alone attenuates
drug-seeking behavior upon re-exposure to contextual cues (two-way ANOVA for repeated measures, time: F1, 24 =
14.32, p=0.0009; interaction (time x treatment): F1,24 = 5.062, p=0.0339; Sidak’s post hoc between last day of
extinction and reinstatement within group comparison, *** p=0.0008).
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A.5 Discussion
The urgency for development of novel pain medication resulted in exciting new targets
which show promising effects in managing nociceptive component of pain, however testing for
misuse liability of such medications is often lacking in the literature. 6,16,17 In this appendix we
assessed mGluR5 NAMs reinforcing properties as a measurement of misuse liability, and panx1
channel blockers as maintenance therapy for prevention of relapse in OUD.
There is compelling evidence that mGluR5 NAMs possess potent analgesic and
antinociceptive properties desirable for treatment of pain, however mGluR5 NAM that have been
previously used in clinical settings did not show suitable pharmacokinetic and pharmacodynamic
properties.5,6 This resulted in development of novel mGluR5 NAM with improved
pharmacological qualities such as VU238.9 While our colleagues are demonstrating its role in
producing analgesia, we show that VU238 does not exert reinforcing properties in operant SA. We
also assessed reinforcing properties of Fenobam, another GluR5 NAM currently used in clinic as
anxiolytic medication. Similarly, we found that Fenobam does not induce drug-taking behavior
either. While Fenobam is approved for the use in clinical setting its pain-relieving properties are
highly variable which makes VU238 a better candidate for treatment of pain.
While VU238 did not lead to drug-taking behavior, we also noticed that in this experiment
rates of fentanyl SA diluted in the same vehicle as VU238 were much lower as compared to the
one diluted in vehicle for fenobam. Indeed, dissolving drugs in solutions containing DMSO could
be aversive, thus our collaborators are currently developing non-aversive VU238 vehicles. In
addition, considering that we tested VU238 and Fenobam SA in pain naïve animals future studies
are needed to assess potential for misuse in animals in pain. Indeed, in this dissertation we
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demonstrate that pain itself alters animal’s hedonic state, which could have an effect on reinforcing
properties of pain-relievers such as mGluR5 NAMs. Lastly, mGluR5 are known to be ubiquitously
expressed in many brain areas thus additional experiments are needed to assess effects of VU238
on other behaviors. To this end Fenobam has shown to impair pain related memories, and it would
be interesting to assess the effects of VU238 in the same paradigm. 8 Although considering that
Fenobam is antinociceptive it represents a confound of whether animal does not remember the
pain experience or simply was not able to detect it.
With finding better pain management strategies it is also important to develop treatments
for patients suffering from OUD, particularly medications to assist with withdrawal and craving
upon ending opioid intake in order to prevent relapse rates. To this end we demonstrate that
Probenecid, a drug currently in use for the treatment of gout, attenuates contextual-cue induced
reinstatement of drug-seeking, a pre-clinical model of relapse. It is important to note that
Probenecid is not effective when given only during extinction (an equivalent of abstinence), but
that continuous treatment with Probenecid during extinction and reinstatement is required for
prevention of drug-seeking behavior. From translational point of view, considering that stressors
and cues associated with drug intake or drug availability are not predictable in everyday life, the
fact that probenecid should be given daily is a favorable effect. However, since Probenecid has an
antinociceptive properties it would be important to assess whether this would have an adverse
effect on well-being of animal (or human in clinical studies) when given daily. Lastly, it is also
crucial to assess that Probenecid itself does not pose a risk of misuse.
In conclusion both Probenecid and VU238 show exciting data for management of pain,
demonstrating the possibility of producing pain relieving effects independent of opioid receptor
system. However, the success of these approaches is only shown in managing nociceptive
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component of pain and it is imperative for future studies to assess whether the same treatments
could be used to alleviate negative affective states accompanying pain as well.
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